<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Hirsch, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert J Birnbaum, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter P Roy-Byrne, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H399779766"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The selective serotonin reuptake inhibitors (SSRIs) include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">Escitalopram</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">Fluoxetine</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">Fluvoxamine</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">Paroxetine</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">Sertraline</a></p><p></p><p>SSRIs are frequently used as first-line antidepressants because of their efficacy and tolerability, as well as their general safety in overdose. In addition, SSRIs are indicated for anxiety disorders, eating disorders, menopausal hot flashes, obsessive-compulsive and related disorders, posttraumatic stress disorder, premature ejaculation, premenstrual dysphoric disorder, and somatic symptom disorder [<a href="#rid1">1</a>].</p><p>This topic reviews the pharmacology of SSRIs, their administration for treating unipolar depression in adults, and their side effects. Sexual dysfunction associated with SSRIs, the serotonin syndrome, and management of SSRI overdose are discussed separately. In addition, choosing initial treatment of depression in adults and managing treatment resistant depression are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1706.html" rel="external">"Sexual dysfunction caused by selective serotonin reuptake inhibitors (SSRIs): Management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/297.html" rel="external">"Selective serotonin reuptake inhibitor poisoning"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14685.html" rel="external">"Unipolar depression in adults: Choosing treatment for resistant depression"</a>.)</p><p class="bulletIndent1"><span class="glyph utd-adt-cnt utd-adt-pathwys">●</span><span class="utd-adt-cnt utd-adt-pathwys utd-content-138287">(Related Pathway(s):  <a class="utd-content-138287" href="/pathway/138287?topicRef=14675&amp;source=see_link">Unipolar major depression: Initial pharmacologic therapy in adults</a>.)</span></p><p></p><p class="headingAnchor" id="H14787857"><span class="h1">PHARMACOLOGY</span></p><p class="headingAnchor" id="H25328730"><span class="h2">Structure</span><span class="headingEndMark"> — </span>The selective serotonin reuptake inhibitors (SSRIs) vary considerably in their chemical structure and activity [<a href="#rid1">1</a>]. As examples, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> and <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> exist as single isomers, whereas <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> and <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> are racemic mixtures of two stereoisomers that are mirror images of each other.</p><p class="headingAnchor" id="H25328749"><span class="h3">Citalopram and escitalopram</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> consists of two stereoisomers that are mirror images of each other and thus not identical in that they cannot be superimposed upon each other (similar to one’s hands) [<a href="#rid2">2</a>]. One of the stereoisomers, S-citalopram (<a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a>), more potently inhibits reuptake of serotonin compared with the other stereoisomer.</p><p class="headingAnchor" id="H399779781"><span class="h2">Pharmacodynamics</span><span class="headingEndMark"> — </span>SSRIs appear to treat depression by increasing serotonergic activity [<a href="#rid1">1-4</a>]. They are selective in that they have relatively little affinity for other types of receptors.</p><p>Serotonin (5-hydroxytryptamine or 5-HT) is an indoleamine neurotransmitter released in the brain from neurons originating in the brainstem raphe nuclei [<a href="#rid1">1,3,4</a>]. Serotonergic neurotransmission in the brain involves at least 14 different types of pre- and postsynaptic serotonin receptors. All SSRIs potently decrease the action of the presynaptic serotonin reuptake pump, by as much as 90 percent [<a href="#rid3">3</a>]. This increases the length of time that serotonin is available in the synapse and increases postsynaptic serotonin receptor occupancy.</p><p>However, reuptake inhibition does not appear to be sufficient for treating depression. Reuptake inhibition occurs soon after SSRIs are started, and the full therapeutic effects of SSRIs may not appear for three to eight (or more) weeks after treatment has started. The full clinical response may require additional “downstream” effects [<a href="#rid5">5</a>]. As an example of one such effect, the initial increase in synaptic serotonin eventually leads to increased production of neuroprotective proteins such as brain-derived neurotrophic factor and Bc1-2 [<a href="#rid6">6</a>]. In addition, treatment with an SSRI for weeks modifies the serotonergic receptors; the changes vary depending upon the serotonin receptor subtype [<a href="#rid1">1,4</a>].</p><p>The relatively benign side effect profile of the SSRIs is due to their selectivity [<a href="#rid1">1,3,4</a>]. None of the SSRIs significantly affect alpha-adrenergic, histaminic, or cholinergic receptors, except for <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, which weakly antagonizes the cholinergic receptor. Side effects that occur with SSRI treatment are attributed primarily to their effects upon serotonin receptors.</p><p class="headingAnchor" id="H399779788"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>The absorption, distribution, metabolism, and elimination of the SSRIs are well described [<a href="#rid7">7-10</a>].</p><p>SSRIs are well absorbed in the gastrointestinal tract and reach peak plasma levels within one to eight hours [<a href="#rid2">2,4,5,7</a>]. Food generally does not affect absorption, except for <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>, which is absorbed more quickly when taken with food. Following absorption, SSRIs bind to plasma proteins and are widely distributed throughout the body, including the brain, because they are lipophilic.</p><p>Metabolism and elimination occur largely in the liver [<a href="#rid7">7</a>]. Metabolism of each SSRI except <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a> produces pharmacologically active metabolites [<a href="#rid5">5</a>]. However, only <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> yields a metabolite (norfluoxetine) that potently inhibits reuptake of serotonin and has antidepressant activity.</p><p>The elimination half-life for the SSRIs is as follows [<a href="#rid1">1-5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> – 36 hours</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">Escitalopram</a> – 36 hours</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">Fluoxetine</a> – 4 to 6 days (active metabolite norfluoxetine 4 to 16 days)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">Fluvoxamine</a> – 15 hours</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">Paroxetine</a> – 24 hours</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">Sertraline</a> – 26 to 32 hours</p><p></p><p class="headingAnchor" id="H399780619"><span class="h2">Drug-drug interactions</span><span class="headingEndMark"> — </span>Some SSRIs are moderate to potent inhibitors of hepatic cytochrome P450 drug metabolism and can cause drug-drug interactions by altering blood levels of other medicines that depend on these enzymes for clearance or activation. <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> and <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> inhibit liver enzymes less than other SSRIs and are thus the SSRIs of choice for situations in which drug-drug interactions are a concern [<a href="#rid7">7,11</a>]. <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">Sertraline</a> is a reasonable alternative [<a href="#rid12">12</a>].</p><p>The specific cytochrome enzymes that each drug and their metabolites potently or moderately inhibit are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> – none</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">Escitalopram</a> – none</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">Fluoxetine</a> – CYP2D6 (potent) and 2C19 (moderate)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">Fluvoxamine</a> – CYP1A2 (potent) and 2C19 (moderate)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">Paroxetine</a> – CYP2D6 (potent)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">Sertraline</a> – none</p><p></p><p>All SSRIs weakly inhibit one or more other cytochrome P450 drug metabolizing enzymes. However, weak inhibition of CYP450 metabolism rarely alters the levels or activity of other medications to a degree that is clinically significant. Additional information about each drug and its inhibition of hepatic enzymes can be found in the individual Lexicomp drug information topics in the section on Metabolism/Transport Effects.</p><p>Among the many potential drug-drug interactions that may occur with SSRIs is the interaction between <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> or <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> and <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>. Tamoxifen is used to treat or prevent recurrence of breast cancer, and is a prodrug that is metabolized by cytochrome P450 2D6 to the active metabolite. Although concerns have been raised that paroxetine or fluoxetine may interact with tamoxifen and interfere with tamoxifen treatment of breast cancer, the clinical significance of the drug-drug interactions is not clear. Nevertheless, we prefer to avoid using CPY2D6 inhibitors with tamoxifen if alternative strategies are available. (See  <a class="medical medical_review" href="/d/html/762.html" rel="external">"Mechanisms of action of selective estrogen receptor modulators and down-regulators", section on 'Patients taking SSRIs'</a>.)</p><p>Another example is the interaction between SSRIs and prodrug opioids. Prodrug opioids, such as <a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">codeine</a>, <a class="drug drug_general" data-topicid="91299" href="/d/drug information/91299.html" rel="external">hydrocodone</a>, and <a class="drug drug_general" data-topicid="10010" href="/d/drug information/10010.html" rel="external">tramadol</a>, are converted to active metabolites (eg, <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>) by hepatic CYP2D6; by contrast, other opioids, such as <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a>, morphine, and <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a>, are effective without metabolism. A nine-year retrospective study of surgical patients with depression (n &gt;4300) found that postoperative pain control was worse in patients who were treated with prodrug opioids plus SSRIs, compared with patients who received prodrug opioids but no SSRIs, non-prodrug opioids plus SSRIs, or non-prodrug opioids but no SSRIs [<a href="#rid13">13</a>].</p><p>Specific interactions of SSRIs with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate.</p><p class="headingAnchor" id="H399779802"><span class="h1">PRESCRIBING SSRIs</span><span class="headingEndMark"> — </span>Treating depression with selective serotonin reuptake inhibitors (SSRIs) requires use of general pharmacotherapy principles as well as knowledge about the proper dose.</p><p>SSRIs are contraindicated in patients with hypersensitivity, as well as patients who received a monoamine oxidase inhibitor (MAOI) in the previous two weeks, because SSRIs and MAOIs can interact to cause the serotonin syndrome. In addition, clinicians should exercise caution in prescribing SSRIs with other serotonergic medications (eg, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or serotonin-norepinephrine reuptake inhibitors)  (<a class="graphic graphic_table graphicRef64604" href="/d/graphic/64604.html" rel="external">table 1</a>), which may also cause the serotonin syndrome. (See  <a class="medical medical_review" href="/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p>Choosing a specific SSRI is based upon individual patient tolerance, cost, and clinician experience, because efficacy across SSRIs appears to be comparable [<a href="#rid1">1,3,4</a>].</p><p class="headingAnchor" id="H399780656"><span class="h2">General principles</span></p><p class="headingAnchor" id="H504526"><span class="h3">Guidelines to review with patients</span><span class="headingEndMark"> — </span>Prior to prescribing SSRIs, clinicians should discuss side effects, time to response, drug interactions, and stopping the medication. (See <a class="local">'Side effects'</a> below.)</p><p>Clinicians should review common side effects and the need to take the medication as prescribed rather than on an as needed basis. Patients should also be informed that although some response may occur within the first two weeks of treatment, it may take up to eight weeks to reach full clinical effect.</p><p>Possible drug interactions should also be reviewed, including other drugs that increase serotonergic activity (eg, MAOIs)  (<a class="graphic graphic_table graphicRef64604" href="/d/graphic/64604.html" rel="external">table 1</a>) and the possibility of the potentially fatal serotonin syndrome. (See <a class="local">'Drug-drug interactions'</a> above and  <a class="medical medical_review" href="/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p>In addition, clinicians should discuss abrupt discontinuation of SSRIs, which may precipitate dysphoria, dizziness, gastrointestinal distress, fatigue, chills, and myalgias. The discontinuation syndrome associated with suddenly stopping SSRIs is discussed separately. (See  <a class="medical medical_review" href="/d/html/105323.html" rel="external">"Discontinuing antidepressant medications in adults", section on 'SSRIs'</a>.)</p><p class="headingAnchor" id="H14789327"><span class="h3">Medical tests and plasma levels</span><span class="headingEndMark"> — </span>No specific medical tests are required before starting an SSRI [<a href="#rid12">12</a>].</p><p>SSRI serum concentrations are rarely performed. Although several indications for serum levels have been proposed, clinical judgment can usually resolve the issue and avoid the problems that are associated with serum concentrations, including uncertainty about their clinical significance, as well as cost and patient inconvenience. As an example, drug levels can theoretically be used to establish that it is safe to begin another serotonergic drug (eg, an MAOI) after discontinuing an SSRI, to avoid the serotonin syndrome [<a href="#rid14">14</a>]. However, clinicians can instead wait for five or more elimination half-lives of the discontinued SSRI or its metabolite, whichever is longer (see <a class="local">'Pharmacokinetics'</a> above), to elapse before starting the new drug [<a href="#rid1">1</a>], unless the depressive syndrome is severe and time is of the essence. Other proposed indications for serum levels include assessing adherence, determining whether patients who do not respond to initial treatment or who relapse during maintenance treatment are rapid metabolizers, determining whether concomitant drugs are affecting SSRI serum concentrations, and monitoring special populations (eg, children and adolescents; patients with intellectual disability; older adult, pregnant, or breastfeeding patients; and patients with hepatic disease or abnormally high or low body weight) [<a href="#rid14">14</a>]. Another possible indication may be problems that occur when switching between a brand-name and generic preparations.</p><p>Although measuring SSRI serum concentrations is not standard practice, several studies have attempted to correlate plasma levels and therapeutic effects. Therapeutic reference ranges suggested by one practice guideline are as follows [<a href="#rid14">14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> – 50 to 110 ng/mL</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">Escitalopram</a> – 15 to 80 ng/mL</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">Fluoxetine</a> plus norfluoxetine – 120 to 500 ng/mL</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">Fluvoxamine</a> – 60 to 230 ng/mL</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">Paroxetine</a> – 20 to 65 ng/mL</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">Sertraline</a> – 10 to 150 ng/mL</p><p></p><p class="headingAnchor" id="H399780663"><span class="h3">Response time</span><span class="headingEndMark"> — </span>Many depressed patients treated with an SSRI respond within one or two weeks, while other patients require several more weeks of treatment (eg, a total of 8 to 12 weeks) [<a href="#rid15">15-17</a>]. Severity of illness, comorbid disease, pharmacodynamic factors, and psychosocial factors may affect how quickly depressed patients respond to treatment with SSRIs.</p><p>Time to response was evaluated in the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In the Sequenced Treatment Alternatives to Relieve Depression study, which included 2876 outpatients; more than 75 percent of the patients had recurrent or chronic depression, and most had multiple comorbid medical and psychiatric illnesses [<a href="#rid17">17</a>]. The average mean time to response (reduction in baseline depression rating scale score ≥50 percent) to <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> was six weeks. Among patients who eventually responded, 56 percent did so at or after eight weeks of treatment. The average mean time to remission was seven weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An open-label study of 384 outpatients with major depression, treated with <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> for eight weeks, evaluated time to sustained response, defined as a 30 percent decrease from the baseline depression rating scale score, which persisted and led to a 50 percent decrease by week 8 [<a href="#rid16">16</a>]. None of the patients had previously failed an adequate antidepressant trial during the current episode. Among the 182 patients who responded, 56 percent responded at week 2, 25 percent at week 4, and 9 percent at week 6 (the cumulative probabilities of response were thus 56, 80, and 90 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of 28 randomized trials (5872 patients with unipolar depression) found that SSRIs begin to have a small clinically beneficial effect beyond the effect of placebo by the end of the first week of treatment [<a href="#rid15">15</a>]. Incremental improvement attributable to the SSRI continued at a decreasing rate for the next five weeks. A second analysis of five studies (1365 patients) showed that response (≥50 percent reduction in baseline depression rating scale score) by week 1 was 60 percent more likely in patients who received an SSRI compared with patients who received placebo (relative risk 1.6, 95% CI 1.2-2.3).</p><p></p><p class="headingAnchor" id="H14788308"><span class="h3">Pregnancy</span><span class="headingEndMark"> — </span>The safety of antenatal SSRIs, individually as well as a class, is discussed separately. (See  <a class="medical medical_review" href="/d/html/89067.html" rel="external">"Antenatal use of antidepressants and the potential risk of teratogenicity and adverse pregnancy outcomes: Selective serotonin reuptake inhibitors"</a>.)</p><p>The role of SSRIs and other antidepressants for antenatal depression is discussed separately. (See  <a class="medical medical_review" href="/d/html/1703.html" rel="external">"Severe antenatal unipolar major depression: Choosing treatment"</a>.)</p><p class="headingAnchor" id="H504779"><span class="h2">Administration</span><span class="headingEndMark"> — </span>The frequency and timing of each dose varies between SSRIs.</p><p>The entire dose of an SSRI is generally taken once a day because the elimination half-life averages approximately 24 hours [<a href="#rid1">1,4,8</a>]. <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">Fluvoxamine</a> is taken in two divided doses when the total daily dose exceeds 100 mg, because it has a shorter half-life [<a href="#rid5">5</a>].</p><p>Clinicians usually advise patients to take SSRIs in the morning to minimize insomnia, although there is no evidence that this side effect is related to dose timing. <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">Fluvoxamine</a> is usually taken at bedtime at doses of 100 mg or less, and patients who experience drowsiness with any SSRI can take the drug at bedtime.</p><p><a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">Sertraline</a> is the only SSRI whose absorption is increased when taken with food. Although taking the other SSRIs on a full stomach will not improve absorption, it may help prevent gastrointestinal distress [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H74872026"><span class="h2">Dose</span><span class="headingEndMark"> — </span>We suggest starting with the lowest minimal effective dose to avoid side effects. Equipotent starting doses for the SSRIs for unipolar major depression are as follows  (<a class="graphic graphic_table graphicRef53818" href="/d/graphic/53818.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> – 20 mg</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">Escitalopram</a> – 10 mg</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">Fluoxetine</a> – 20 mg</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">Fluvoxamine</a> – 50 to 100 mg</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">Paroxetine</a> – 20 mg</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">Sertraline</a> – 50 mg</p><p></p><p>In patients who are sensitive to side effects, it may help to start at a subtherapeutic dose for a few days to improve tolerability and then increase the dose to the minimum therapeutic dose. As an example, depressed patients with a comorbid anxiety disorder may tolerate the medication better by starting with half of the suggested dose.</p><p>Dose adjustments are made slowly, with increases as needed according to patient response, tolerability, and clinical urgency. Target doses vary depending upon the patient’s specific disorder.</p><p>Finding the effective dose involves a process of trial and error. In the absence of intolerable side effects, a trial of two to six weeks (often four weeks) at the minimum therapeutic dose is often appropriate to assess response before adjusting the dose or implementing other treatment options. The dose can generally be increased every one to four weeks, depending upon response and tolerability. More frequent titration (eg, every three to six days) may be appropriate in urgent cases with close monitoring, such as inpatients. Although genotype testing (eg, CYP2D6 and CYP2C19 polymorphisms) is available to guide choosing a specific SSRI and dosing the drug [<a href="#rid18">18</a>], the tests are not standard practice and we suggest not using them because of the preliminary nature of the data that underlie the tests and lack of compelling evidence that they affect outcomes in clinical practice.</p><p>Fixed dose randomized trials of SSRIs indicate that efficacy in unipolar major depression increases with increased doses, but that tolerability decreases. As an example, a dose-response meta-analysis included 66 randomized trials of SSRIs that generally lasted six to eight weeks and evaluated various fixed doses in a total of 99 active treatment arms [<a href="#rid19">19</a>]. Doses for the different SSRIs were converted to <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> equivalents. Response (reduction of baseline symptoms ≥50 percent) with SSRIs increased as the dose increased to approximately 20 to 40 mg/day fluoxetine equivalents, with no further benefit up to 80 mg/day fluoxetine equivalents. However, as the dose of SSRIs increased, discontinuation of treatment due to adverse effects also increased, suggesting that the optimal balance between response and tolerability may be achieved at 20 to 40 mg/day fluoxetine equivalents.</p><p>Although fixed-dose trials provide a rigorous means for assessing dose-response relationships, these trials can lead to early, intolerable side effects in patients assigned to relatively high doses because the protocols call for rapid- or no-dose titration. By contrast, flexible-dose trials better approximate clinical practice by allowing clinicians to titrate the dose according to both response and tolerability.</p><p>Flexible-dose trials also indicate that higher doses within the therapeutic range can be beneficial [<a href="#rid20">20</a>]. As an example, a meta-analysis examined 40 randomized trials of SSRIs, including flexible-dose trials, with 49 active treatment arms [<a href="#rid21">21</a>]. The results found that a dose greater than 50 mg/day <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> equivalents was modestly superior to 20 mg/day fluoxetine equivalents (odds ratio 1.3, 95% CI 1.1-1.5).</p><p>Patients who recover from an episode of major depression should receive maintenance treatment with the full dose that successfully resolved the episode, rather than a lower dose. (See  <a class="medical medical_review" href="/d/html/14674.html" rel="external">"Unipolar depression in adults: Continuation and maintenance treatment", section on 'Dose'</a>.)</p><p class="headingAnchor" id="H7700689"><span class="h3">Citalopram</span><span class="headingEndMark"> — </span>We suggest an initial dose of 20 mg in the morning  (<a class="graphic graphic_table graphicRef53818" href="/d/graphic/53818.html" rel="external">table 2</a>). Older patients and those sensitive to side effects can be started at a dose of 10 mg. The target dose range is 20 to 40 mg once per day [<a href="#rid22">22-24</a>]. The dose can be titrated up in increments of 10 or 20 mg per day, every one to four weeks.</p><p>The maximum dose of <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> is nearly always 40 mg/day, based upon recommendations from the US Food and Drug Administration (FDA) [<a href="#rid25">25</a>]. The FDA issued a warning that citalopram can cause dose-dependent prolongation of the corrected QT interval, which can lead to a life-threatening cardiac arrhythmia, torsade de pointes [<a href="#rid25">25</a>]. A subsequent warning recommended a maximum dose of 20 mg per day in patients with risk factors for increased serum concentrations of citalopram [<a href="#rid26">26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic impairment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;60 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CYP2C19 variants that slowly metabolize <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concomitant medications that inhibit CYP2C19. Specific interactions of <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate.</p><p></p><p>Furthermore, <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> should be avoided in patients with congenital long QT syndrome, persistent corrected QT measurements &gt;500 milliseconds, bradycardia, hypokalemia, hypomagnesemia, recent myocardial infarction, or uncompensated heart failure, as well as patients taking other drugs that prolong the QT interval.</p><p>It may be reasonable to prescribe doses greater than those recommended by the FDA, such as patients who achieve an incomplete response to <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> after failing other antidepressants [<a href="#rid2">2,27,28</a>]. Nevertheless, clinicians should exercise great care when exceeding the FDA guidance. If clinicians prescribe citalopram at doses &gt;40 mg/day, or &gt;20 mg per day in patients at risk for increased serum concentrations, we suggest first reviewing a baseline electrocardiogram (ECG) [<a href="#rid28">28</a>]. In addition, we suggest an ECG when starting citalopram in any patient receiving concurrent medications that can prolong the QTc interval and patients who are suffering palpitations or syncope. Additional information about the cardiac effects of citalopram and other SSRIs is discussed elsewhere in this topic. (See <a class="local">'Cardiac'</a> below.)</p><p>The FDA does not make any recommendation about testing for CYP2C19 poor metabolizers, nor is it standard practice to test patients who will receive <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>.</p><p>A liquid concentrate formulation is available.</p><p class="headingAnchor" id="H7700696"><span class="h3">Escitalopram</span><span class="headingEndMark"> — </span>We suggest an initial dose of 10 mg in the morning  (<a class="graphic graphic_table graphicRef53818" href="/d/graphic/53818.html" rel="external">table 2</a>). Older patients and those sensitive to side effects can be started at a dose of 5 mg.</p><p>The standard dose range for unipolar major depression is 10 to 20 mg once per day [<a href="#rid22">22-24</a>]. The dose can be titrated up in increments of 5 or 10 mg per day, after one to four weeks. Doses up to 30 mg per day have been used.</p><p><a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">Escitalopram</a> is a single isomer formulation of <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>, and the FDA has issued warnings that citalopram causes dose-dependent QT interval prolongation that can lead to arrhythmias (see <a class="local">'Citalopram'</a> above) [<a href="#rid25">25,26</a>]. Although an analysis of a randomized trial by the FDA found that escitalopram also caused dose-dependent QT interval prolongation, the finding was not deemed clinically significant, and no warning was issued regarding escitalopram. Cardiac effects of escitalopram and other SSRIs and the structural relationship between escitalopram and citalopram are discussed elsewhere in this topic. (See <a class="local">'Cardiac'</a> below and <a class="local">'Citalopram and escitalopram'</a> above.)</p><p>A liquid concentrate formulation is available.</p><p class="headingAnchor" id="H399781192"><span class="h3">Fluoxetine</span><span class="headingEndMark"> — </span>We suggest an initial dose of 20 mg in the morning  (<a class="graphic graphic_table graphicRef53818" href="/d/graphic/53818.html" rel="external">table 2</a>). Older patients and those sensitive to side effects can be started at a dose of 10 mg.</p><p>In addition, patients with clinically significant anxiety/agitation or insomnia can be started at a dose of 5 mg.</p><p>The standard dose range for unipolar major depression is 20 to 60 mg once per day [<a href="#rid22">22-24</a>]. The dose can be titrated up in increments of 10 or 20 mg per day, every four weeks. Doses up to 80 mg per day have been used.</p><p>Other formulations of <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> are available, including a liquid concentrate. In addition, there is a 90 mg delayed release capsule taken once per week. Patients must be stabilized on fluoxetine 20 mg daily prior to switching to once-weekly dosing. The manufacturer recommends waiting seven days after the last 20 mg daily dose of fluoxetine before beginning the once weekly regimen with the 90 mg delayed release formulation.</p><p class="headingAnchor" id="H7700832"><span class="h3">Fluvoxamine</span><span class="headingEndMark"> — </span>We suggest an initial dose of 50 mg at bedtime  (<a class="graphic graphic_table graphicRef53818" href="/d/graphic/53818.html" rel="external">table 2</a>). Older patients and those sensitive to side effects can be started at a dose of 25 mg.</p><p>The standard dose range for unipolar major depression is 100 to 200 mg per day [<a href="#rid22">22,23,29-31</a>]. The dose can be titrated up from the starting dose of 50 mg by increments of 25 or 50 mg per day, every several days to two weeks. When the dose exceeds 100 mg per day, it should be given in two divided doses. The two doses may be either equal, or a larger portion may be given at bedtime. The dose may be increased further by increments of 50 mg per day, every several days to two weeks. Doses up to 300 mg per day have been used.</p><p>It is also available in an extended-release formulation (100 and 150 mg) for once per day dosing at higher doses.</p><p class="headingAnchor" id="H399779823"><span class="h3">Paroxetine</span><span class="headingEndMark"> — </span>We suggest an initial dose of 20 mg in the morning  (<a class="graphic graphic_table graphicRef53818" href="/d/graphic/53818.html" rel="external">table 2</a>). Older patients and those sensitive to side effects can be started at a dose of 10 mg.</p><p>The standard dose range for unipolar major depression is 20 to 40 mg once per day [<a href="#rid22">22-24</a>]. The dose can be titrated up in increments of 10 or 20 mg per day, every one to four weeks. The maximum dose is 50 mg per day.</p><p>Other formulations of <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> are available, including a liquid concentrate. In addition, there is an enteric coated, controlled-release formulation. It may cause less nausea than the immediate release formulation for patients who are experiencing this adverse effect; otherwise, there is no compelling reason to change from one formulation to the other. The controlled-release formulation has less bioavailability, thus, a 12.5 mg dose of the controlled-release formulation is equivalent to 10 mg of regular release paroxetine. The recommended starting dose of the controlled-release formulation is 25 mg/day; the maximum dose may be as high as 75 mg/day, depending upon the indication.</p><p class="headingAnchor" id="H7700895"><span class="h3">Sertraline</span><span class="headingEndMark"> — </span>We suggest an initial dose of 50 mg in the morning  (<a class="graphic graphic_table graphicRef53818" href="/d/graphic/53818.html" rel="external">table 2</a>). Older patients and those sensitive to side effects can be started at a dose of 25 mg.</p><p>The standard dose range for unipolar major depression is 50 to 200 mg once per day [<a href="#rid22">22-24</a>]. The dose can be titrated up in increments of 25 or 50 mg per day, every one to four weeks. Doses up to 300 mg per day have been used.</p><p>A liquid concentrate formulation is available.</p><p><a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">Sertraline</a> reaches its peak plasma concentration sooner when taken with food [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H399779851"><span class="h1">SIDE EFFECTS</span></p><p class="headingAnchor" id="H399780694"><span class="h2">Overview</span><span class="headingEndMark"> — </span>The selective serotonin reuptake inhibitors (SSRIs) tend to have similar side effect profiles [<a href="#rid1">1</a>]. However, certain SSRIs may be more likely to cause specific side effects  (<a class="graphic graphic_table graphicRef62488" href="/d/graphic/62488.html" rel="external">table 3</a>) [<a href="#rid32">32</a>]. Thus, some patients who cannot tolerate one SSRI may do well with another [<a href="#rid12">12</a>].</p><p>The SSRIs are often first-line treatment for depression because they are better tolerated than tricyclics or monoamine oxidase inhibitors [<a href="#rid1">1,4,12,32,33</a>]. In three-arm randomized trials, discontinuation of treatment because of an adverse event was typically lowest for placebo (5 to 10 percent), intermediate for the SSRI (10 to 20 percent), and highest for the tricyclic (30 to 35 percent) [<a href="#rid1">1</a>]. However, it is not clear that SSRIs are better tolerated than other antidepressant classes, such as atypical antidepressants (eg, <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a> and <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a>) and serotonin-norepinephrine reuptake inhibitors (SNRIs).</p><p>Based upon randomized trials, the most frequent and troublesome adverse effects of SSRIs include [<a href="#rid1">1-5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Nausea – Most common</p><p class="bulletIndent1"><span class="glyph">●</span>Dry mouth</p><p class="bulletIndent1"><span class="glyph">●</span>Headache</p><p class="bulletIndent1"><span class="glyph">●</span>Insomnia</p><p class="bulletIndent1"><span class="glyph">●</span>Loose stools/diarrhea</p><p class="bulletIndent1"><span class="glyph">●</span>Sexual dysfunction</p><p class="bulletIndent1"><span class="glyph">●</span>Somnolence</p><p class="bulletIndent1"><span class="glyph">●</span>Sweating</p><p class="bulletIndent1"><span class="glyph">●</span>Tremor</p><p class="bulletIndent1"><span class="glyph">●</span>Weight change</p><p></p><p>Additional information about sexual dysfunction and weight change are described elsewhere. (See  <a class="medical medical_review" href="/d/html/1706.html" rel="external">"Sexual dysfunction caused by selective serotonin reuptake inhibitors (SSRIs): Management"</a> and <a class="local">'Weight change'</a> below.)</p><p>Other SSRI side effects identified in randomized trials and observational studies include anxiety, asthenia (daytime sedation associated with malaise, diminished mental energy, or emotional blunting), bleeding, coagulopathy, bone fractures, dizziness, extrapyramidal symptoms (eg, akathisia, dystonias, and parkinsonism), and hyponatremia [<a href="#rid1">1-5,32-34</a>]. (See <a class="local">'Bleeding'</a> below and  <a class="medical medical_review" href="/d/html/2036.html" rel="external">"Drugs that affect bone metabolism", section on 'Antidepressants'</a> and <a class="local">'Hyponatremia'</a> below.)</p><p>While any SSRI can cause side effects, there are a few general trends in side effect frequency [<a href="#rid3">3,32,35</a>]. Nausea and sedation may be more likely to occur with <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> and <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a>, diarrhea with <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>, activation may be more likely to occur with <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> and sertraline, and sexual dysfunction may be more likely with paroxetine. Weight gain and anticholinergic side effects most common with paroxetine.</p><p>Although side effects that occur at the onset of treatment can persist beyond three months of treatment [<a href="#rid33">33</a>], many are transient and remit [<a href="#rid1">1</a>]. Reducing the dose may help alleviate the problem if the dose was previously titrated up. Dividing the dose during the day may also help. Nausea, which is the most common side effect and is often distressing, can be mitigated by starting the drug at a relatively low dose and administering the drug with food [<a href="#rid3">3</a>].</p><p>Additional information about SSRI adverse effects are described elsewhere. (See  <a class="medical medical_review" href="/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment", section on 'Side effects'</a>.)</p><p class="headingAnchor" id="H399780701"><span class="h2">Suicide risk</span><span class="headingEndMark"> — </span>There is no clear evidence that treating depressed patients with SSRIs, or antidepressants in general, increases or decreases the risk of suicidality (suicidal ideation, preparatory act, attempt, or death) [<a href="#rid36">36,37</a>]. However, there may be an age-specific effect of antidepressants upon suicidality. Antidepressants in general may raise the risk of suicidal ideation slightly in patients age 18 to 24 years, have no effect upon patients age 25 to 30 years, and may lower the risk in patients 31 years and older. In addition, untreated depression can lead to suicidality. Some studies suggest that the risk of suicidality among different SSRIs is comparable [<a href="#rid3">3</a>] and that the risk of suicidality is comparable with SSRIs and placebo [<a href="#rid2">2,4</a>].</p><p>Suicidal ideation and behavior in adults and the potential effect of SSRIs on suicidal ideation and behavior in adults and children are discussed separately. (See  <a class="medical medical_review" href="/d/html/1708.html" rel="external">"Suicidal ideation and behavior in adults"</a> and  <a class="medical medical_review" href="/d/html/14672.html" rel="external">"Effect of antidepressants on suicide risk in adults"</a> and  <a class="medical medical_review" href="/d/html/1225.html" rel="external">"Effect of antidepressants on suicide risk in children and adolescents"</a>.)</p><p class="headingAnchor" id="H31651631"><span class="h2">Cardiac</span><span class="headingEndMark"> — </span>SSRIs are generally safe with regard to adverse cardiac effects and are considered the safest antidepressants for treating patients with comorbid cardiovascular disease  (<a class="graphic graphic_table graphicRef62488" href="/d/graphic/62488.html" rel="external">table 3</a>) [<a href="#rid38">38</a>].</p><p>Although SSRIs can prolong the QT interval (corrected for heart rate), the clinical effect is often small. In a meta-analysis of 10 trials (n = 2599 patients) that compared SSRIs with placebo, SSRIs were associated with an increase in the corrected QT interval of 6 milliseconds, and prolongation was dose dependent [<a href="#rid39">39</a>]. The SSRI with the highest value for QTc prolongation was <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>. (See <a class="local">'Citalopram'</a> below.)</p><p>Other studies suggest that QT prolongation in patients treated with SSRIs is generally not clinically serious. A study of an administrative health care database included patients with a first diagnosis of depression (n &gt;230,000) who were followed for a median of five years [<a href="#rid40">40</a>]. After adjusting for potential confounding factors (eg, age, smoking, severity of depression, and general medical illnesses such as hypertension and diabetes), the analyses found that the risk of a first diagnosis of arrythmia was comparable in patients treated with SSRIs and patients not treated with antidepressants.</p><p>Risk factors for a serious arrhythmia due to drug-induced QTc prolongation include [<a href="#rid28">28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Baseline QT prolongation</p><p class="bulletIndent1"><span class="glyph">●</span>Underlying heart disease (particularly heart failure, myocardial infarction [MI], and left ventricular hypertrophy)</p><p class="bulletIndent1"><span class="glyph">●</span>Bradycardia</p><p class="bulletIndent1"><span class="glyph">●</span>Electrolyte derangements (especially hypokalemia and hypomagnesemia)</p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent use of more than one drug that can prolong the QT interval</p><p class="bulletIndent1"><span class="glyph">●</span>Female sex</p><p class="bulletIndent1"><span class="glyph">●</span>Advanced age (eg, &gt;60 years)</p><p></p><p>Specific interactions of SSRIs with other medications that may increase the risk of QTc prolongation can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate. In addition, an internet resource with updated lists of specific drugs that prolong the QT interval is available at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.crediblemeds.org%2F&amp;token=F2fTJXWTbAdqtiUVhUGfEeHvm%2Bapw8j0DIpr7ZimhTcQDLZbSKKNNIJ4B%2FwprPZ%2F&amp;TOPIC_ID=14675" target="_blank">University of Arizona Center for Education and Research on Therapeutics website</a>.</p><p>Additional information about QT prolongation is discussed separately. (See  <a class="medical medical_review" href="/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a> and  <a class="medical medical_review" href="/d/html/116011.html" rel="external">"Acquired long QT syndrome: Clinical manifestations, diagnosis, and management"</a>.)</p><p>Multiple studies indicate that SSRIs are not associated with onset of coronary heart disease (eg, MI):</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 16 observational studies that included more than 750,000 subjects with no history of coronary heart disease, the risk of coronary heart disease for patients treated with SSRIs and controls was comparable [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent study of an administrative health care database included patients with a first diagnosis of depression (n &gt;230,000) who were followed for a median of five years [<a href="#rid40">40</a>]. In year 1 of follow-up, the risk of a first diagnosis of MI was lower in patients treated with SSRIs than patients not treated with antidepressants (adjusted hazard ratio 0.6, 95% CI 0.4-0.8). Over five years of follow-up, the risk of a first diagnosis of MI in patients treated with SSRIs and patients not treated with antidepressants was comparable.</p><p></p><p class="headingAnchor" id="H4145433"><span class="h3">Citalopram</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> causes dose-dependent QT interval prolongation, which potentially may lead to a life-threatening cardiac arrhythmia, torsade de pointes (a form of polymorphic ventricular tachycardia):</p><p class="bulletIndent1"><span class="glyph">●</span>An analysis by the US Food and Drug Administration (FDA) of a randomized trial (n = 119) found that the maximum mean prolongation in the individually corrected QT intervals was longer for <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> 60 mg per day (18.5 milliseconds, 90% CI 16.0-21.0) compared with 20 mg per day (8.5 milliseconds, 90% CI 6.2-10.8) [<a href="#rid25">25,26,42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition, a randomized trial compared <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> (target dose 30 mg per day) with placebo in patients with Alzheimer disease and agitation (n = 48; mean age approximately 78 years) [<a href="#rid43">43</a>]. Increases in corrected QT interval were greater with citalopram and an increase &gt;30 milliseconds occurred in more patients who received citalopram than placebo (7 versus 1 patient).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple retrospective studies have also found an association between increasing doses of <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> and corrected QT interval prolongation [<a href="#rid42">42,44,45</a>].</p><p></p><p>Based upon the finding that <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> causes dose-dependent QT prolongation, the FDA issued a safety warning about using doses &gt;40 mg/day and also warned that citalopram should be avoided in patients with congenital long QT syndrome, persistent corrected QT measurements &gt;500 milliseconds, bradycardia, hypokalemia, hypomagnesemia, recent MI, or uncompensated heart failure, as well as patients taking other drugs that prolong the QT interval (see <a class="local">'Citalopram'</a> above). Warnings about citalopram and QT prolongation have been issued by other regulatory agencies, including Medicines and Healthcare Products Regulatory Agency of the United Kingdom, Health Canada, and the Therapeutic Goods Administration of Australia [<a href="#rid28">28</a>].</p><p>However, the warnings about <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> are controversial, due to the magnitude of the prolongation in corrected QT intervals (approximately 10 to 20 milliseconds), which are clinically insignificant in the absence of other risk factors for arrythmias [<a href="#rid28">28</a>]. In addition, multiple retrospective studies of administrative health care databases suggest that relatively high doses of citalopram (eg, &gt;40 mg/day) are not associated with cardiac arrhythmias [<a href="#rid46">46</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Data from the United States Veterans Health Administration:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One study identified depressed patients who were prescribed <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> (n &gt;610,000) and found that after adjusting for potentially confounding sociodemographic and clinical factors, the risk of ventricular arrhythmia was less with daily doses &gt;40 mg compared with doses ≤20 mg (hazard ratio 0.7, 95% CI 0.6-0.8) [<a href="#rid47">47</a>]. In addition, the risk of cardiac mortality was comparable for the two dose regimens.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another study included patients who were prescribed <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> at a dose &gt;40 mg/day prior to the FDA safety warnings; subsequently, the doses were reduced to 40 mg/day or less (n &gt;14,000) over one year, or were not reduced (n &gt;14,000) [<a href="#rid48">48</a>]. After adjusting for the probability (propensity) of a dose reduction and for potential confounders observed at baseline, the analyses showed that the composite outcome of arrythmia-related hospitalizations or all-cause deaths was comparable in the two groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data from other health care databases:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One study included primary care patients with a first diagnosis of depression (n &gt;230,000) who were followed for a median of five years [<a href="#rid40">40</a>]. After adjusting for potentially confounding factors (eg, age, smoking, severity of depression, and general medical illnesses such as hypertension and diabetes), the analyses found that the risk of a first diagnosis of arrythmia was comparable in patients treated with <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> ≥40 mg/day and patients not treated with antidepressants.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 14-year study examined sudden cardiac death as a proxy for proarrhythmic effects in patients (total n &gt;54,000) who were prescribed relatively high doses of SSRIs: <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, or <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> &gt;40 mg/day, or <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> &gt;150 mg/day, prior to the FDA safety warnings [<a href="#rid49">49</a>]. After adjusting for potentially confounding factors (eg, age, other medications, and general medical illnesses), the analyses found that the risk of sudden cardiac death was comparable among the four SSRIs.</p><p></p><p>Problems that undermine the validity of these low-quality studies include residual confounding and selection bias (eg, prescribing clinicians may have prescribed lower doses to patients at greater risk of arrhythmia) [<a href="#rid50">50,51</a>].</p><p class="headingAnchor" id="H4145439"><span class="h3">Escitalopram</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">Escitalopram</a>, the single isomer formulation of <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>, may also prolong the corrected QT interval [<a href="#rid45">45</a>]. In a randomized trial (n = 113 healthy volunteers), the FDA found that the maximum mean prolongation in the individually corrected QT intervals was longer for escitalopram 30 mg per day (10.7 milliseconds, 90% CI 8.7-12.7) compared with 10 mg per day (4.5 milliseconds, 90% CI 2.5-6.4); however, the FDA concluded that the finding was not clinically significant and did not justify a warning [<a href="#rid28">28</a>]. (See <a class="local">'Escitalopram'</a> above.)</p><p>Randomized trials suggest that <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a>, at doses less than 30 mg/day, does not cause clinically significant QT prolongation [<a href="#rid42">42</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of 14 randomized trials, lasting 8 to 12 weeks, evaluated electrocardiograms in 3689 patients with psychiatric disorders who were randomly assigned to <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> (5 to 20 mg/day) or placebo [<a href="#rid52">52</a>]. The difference between the two groups in the mean change in the corrected QT interval was only 3.5 milliseconds. In three other randomized trials (total n = 670 patients), lasting 24 weeks, the difference between the two groups was 0.8 milliseconds.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A one-year randomized trial compared <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> 10 mg/day with placebo as prophylaxis against depression in patients with recent acute coronary syndrome (n = 240) [<a href="#rid53">53</a>]. Each of the cardiovascular safety measures, including the length of the corrected QT intervals as well as the incidence of ventricular arrythmia and episodes of ST-segment depression, was comparable in the two groups.</p><p></p><p>In addition, low-quality data also indicate that <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> is not associated with clinically significant QT prolongation. As an example, a 14-year retrospective study of an administrative health care database examined sudden cardiac death as a proxy for proarrhythmic effects in patients (total n &gt;54,000) who were prescribed relatively high doses of SSRIs: escitalopram &gt;20 mg/day, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> or <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> &gt;40 mg/day, or <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> &gt;150 mg/day, prior to the FDA safety warnings about <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> (see <a class="local">'Citalopram'</a> above) [<a href="#rid49">49</a>]. After adjusting for potentially confounding factors (eg, age, concurrent medications, and general medical illnesses), the analyses found that the risk of sudden cardiac death was comparable among the four SSRIs.</p><p>However, other low-quality data suggest that <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> at therapeutic doses may possibly be associated with greater QT prolongation than previously appreciated. Cases of clinically significant QTc prolongation with escitalopram have been reported [<a href="#rid54">54,55</a>]; small, prospective observational studies found QT prolongation and variability [<a href="#rid56">56,57</a>]; and a World Health Organization pharmacovigilance database received reports that suggested an increased likelihood of QT prolongation with escitalopram and <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> relative to other SSRIs [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H2352446507"><span class="h3">Other SSRIs</span><span class="headingEndMark"> — </span>There is no compelling evidence that <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a>, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, and <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> cause QT prolongation, and they appear to be unlikely to cause serious arrhythmia when used in usual recommended doses and in patients without other risk factors [<a href="#rid28">28,42</a>]. The SSRIs with the lowest risk of QT prolongation may be fluoxetine [<a href="#rid40">40</a>] and paroxetine [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H516881"><span class="h2">Serotonin syndrome</span><span class="headingEndMark"> — </span>Serotonin syndrome is a potentially lethal condition caused by overstimulation of central and peripheral serotonin receptors. It typically results from an interaction between multiple medications that increase serotonergic neurotransmission  (<a class="graphic graphic_table graphicRef64604" href="/d/graphic/64604.html" rel="external">table 1</a>). However, the syndrome can occur after initiating or increasing a single serotonergic drug. Clinical features include anxiety, agitation, delirium, diaphoresis, tachycardia, hypertension, hyperthermia, gastrointestinal distress, tremor, muscle rigidity, myoclonus, and hyperreflexia. It is not known whether SSRIs differ in their likelihood to cause this syndrome.</p><p>A rapid overview of the clinical features and management of the serotonin syndrome is provided in the table  (<a class="graphic graphic_table graphicRef73400" href="/d/graphic/73400.html" rel="external">table 4</a>). Additional information about the serotonin syndrome is discussed separately. (See  <a class="medical medical_review" href="/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p class="headingAnchor" id="H399780708"><span class="h2">Sexual dysfunction and infertility</span><span class="headingEndMark"> — </span>SSRIs can cause sexual dysfunction. The incidence, assessment, and management of SSRI induced sexual dysfunction is discussed separately. (See  <a class="medical medical_review" href="/d/html/1706.html" rel="external">"Sexual dysfunction caused by selective serotonin reuptake inhibitors (SSRIs): Management"</a>.)</p><p>It is not known if SSRIs interfere with fertility. One review examined whether SSRIs adversely affected fecundability in women, and identified only two relevant studies that yielded conflicting results [<a href="#rid59">59</a>]. The review also identified seven studies that examined whether SSRIs impacted fertility in males, and found that in six of the studies, SSRIs were associated with abnormal semen parameters. However, all seven studies were observational studies rather than randomized trials, including two studies that were case reports with a total of three patients, and two other studies with a total sample of 60 patients. In addition, some of these six studies failed to account for the potential confounding effect of depression.</p><p class="headingAnchor" id="H399780715"><span class="h2">Weight change</span><span class="headingEndMark"> — </span>The effect of SSRIs upon weight depends upon the specific medication prescribed and the length of treatment. Short-term treatment for two to three months with SSRIs usually causes little or no weight change [<a href="#rid60">60-66</a>]. However, short-term therapy is not clinically appropriate for most patients.</p><p>Although treatment with SSRIs for longer periods of time may result in weight gain, in some cases it is not clear if this is a true medication side effect or the result of recovery from depression and the reversal of undesired weight loss. The evidence suggests that <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> may be the least problematic SSRI regarding undesired weight gain and that <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> may the most problematic [<a href="#rid67">67-69</a>]. Studies lasting between 6 and 30 months have reported the following weight effects:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">Fluoxetine</a> leads to small weight changes ranging from a loss of 0.2 percent of body weight at baseline [<a href="#rid70">70</a>] to a gain of 0.9 percent [<a href="#rid60">60</a>]. A one-year randomized trial showed a mean weight gain of 3.0 kg (6.6 lb) for fluoxetine, compared with 3.2 kg (7.0 lb) for placebo [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> leads to weight changes ranging from none [<a href="#rid71">71</a>] to a mean gain of 2.5 percent of baseline body weight [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">Fluvoxamine</a> leads to a mean weight gain of 2.6 percent of baseline body weight [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">Paroxetine</a> leads to weight gain in 6 percent of patients [<a href="#rid72">72</a>], ranging from 1.6 to 3.6 percent of baseline body weight [<a href="#rid60">60,70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">Sertraline</a> leads to a mean weight gain ranging from 1.0 to 1.6 percent of baseline body weight [<a href="#rid60">60,70</a>]. A randomized trial showed a mean weight gain of 1.5 kg (3.3 lb) for sertraline, compared with 1.8 kg (4.0 lb) for placebo [<a href="#rid73">73</a>].</p><p></p><p>Most studies have evaluated patients suffering from major depressive disorder. It is not clear whether weight change caused by SSRIs differs according to different demographic profiles such as age or sex.</p><p>A review found that weight gain during treatment with SSRIs may be due to remission of major depression, improved appetite, increased carbohydrate craving, and changes in serotonin 2C receptor activity [<a href="#rid74">74</a>]. In addition, weight gain during SSRI treatment is significantly related to poor appetite at the beginning of treatment [<a href="#rid61">61</a>], and there may be a genetic component involving polymorphisms in the catechol-O-methyltransferase gene [<a href="#rid75">75</a>].</p><p>Weight gain due to long-term treatment with SSRIs may lead to diabetes mellitus. An observational study of patients with depression found that use of moderate to high daily doses of SSRIs for periods greater than 24 months was associated with a two-fold increased risk of developing diabetes mellitus, compared with not using antidepressants (incidence rate ratio 2.06, 95% CI 1.20-3.52) [<a href="#rid76">76</a>]. Analysis of individual antidepressants found an increased risk estimate for <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> (incidence rate ratio 1.33, 95% CI 1.02-1.73), suggesting the possibility that the increased risk for SSRIs might have been primarily due to paroxetine.</p><p class="headingAnchor" id="H12543449"><span class="h2">Bleeding</span><span class="headingEndMark"> — </span>SSRIs may be associated with bleeding [<a href="#rid1">1,38</a>], but the evidence is not compelling and we suggest that clinicians should generally not change their practice with regard to using SSRIs [<a href="#rid77">77</a>]. Among the different SSRIs, there is little indication that any specific SSRI is more strongly associated with bleeding [<a href="#rid78">78</a>].</p><p>Although many observational studies have found that SSRIs are associated with abnormal bleeding [<a href="#rid78">78-80</a>], the increased risk is typically small and serious events are rare [<a href="#rid81">81</a>]. In addition, observational studies provide low-quality evidence. The association between SSRIs and bleeding in observational studies may be confounded by many factors, such as intracranial small vessel disease, diabetes mellitus, smoking, and alcohol abuse. In addition, depressed patients who received SSRIs may have been compared with healthy controls; thus, observed associations between SSRI exposure and bleeding may be confounded by exposure to depression (confounding by indication).</p><p>By contrast, high-quality studies (randomized trials) suggest that SSRIs do not cause bleeding [<a href="#rid82">82,83</a>]. However, these studies are too small to identify a low-risk event.</p><p>Bleeding complications of SSRIs identified in observational studies include serious events such as upper gastrointestinal bleeding, stroke, postpartum hemorrhage, and perioperative bleeding, as well as less serious problems such as easy bruising, petechiae and purpura, epistaxis, and hematomas [<a href="#rid84">84,85</a>]. A meta-analysis of 42 observational studies (n &gt;1.4 million patients) found that the risk of serious bleeding was greater in SSRI users than controls (odds ratio 1.4, 95% CI 1.3-1.6) [<a href="#rid86">86</a>]. The association between SSRI exposure and abnormal bleeding across multiple studies appears to be more consistent with upper gastrointestinal bleeding than perioperative bleeding or stroke [<a href="#rid84">84-86</a>]. In addition, the risk of bleeding generally appears to be limited to the time of current use of SSRIs rather than recent or past use, and the risk may be greatest relatively early during SSRI treatment, such as the first 30 days.</p><p>The association between SSRIs and bleeding in observational studies can be amplified by other medications that can cause bleeding, such as nonsteroidal anti-inflammatory drugs (NSAIDs; eg, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a>, or <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a>), other antiplatelet agents (eg, <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>), or anticoagulants (eg, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>) [<a href="#rid80">80,84,85,87</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study compared the risk of intracranial hemorrhage in patients exposed to antidepressants plus NSAIDs with patients exposed to antidepressants alone (total n &gt;4,000,000) [<a href="#rid88">88</a>]. Antidepressants consisted of SSRIs, SNRIs, and tricyclics; propensity scoring was used to match the two groups for observed potential confounders (eg, age, comorbidity, and exposure to other medications). The risk of bleeding within 30 days of drug use was higher with antidepressants plus NSAIDs compared with antidepressants alone (hazard ratio 1.6, 95% CI 1.3-1.9).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of five studies (number of patients not reported) found that intracranial bleeding was greater in patients treated with SSRIs plus oral anticoagulants than oral anticoagulants alone (relative risk 1.6, 95% CI 1.3-1.8) [<a href="#rid89">89</a>].</p><p></p><p>Nevertheless, other observational studies of patients treated with SSRIs found that concomitant use of antiplatelet agents or anticoagulants did not increase the risk of bleeding [<a href="#rid78">78</a>].</p><p>The biological plausibility of the association between SSRIs and increased bleeding is supported by the finding that SSRIs can block the serotonin transporter, inhibit serotonin uptake into platelets, and decrease intraplatelet serotonin concentrations, which may reduce platelet aggregation [<a href="#rid84">84,85</a>]. SSRIs may also increase gastric acid secretion, which can render patients more susceptible to gastrointestinal bleeding.</p><p>In addition, multiple studies suggest that the risk of bleeding may perhaps be greater with antidepressants that bind more tightly to the serotonin transporter and are relatively strong inhibitors of serotonin reuptake, compared with weak inhibitors of serotonin reuptake [<a href="#rid85">85</a>]. As an example, one retrospective study found that the bleeding occurred more often with strong inhibitors of serotonin reuptake (eg, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, and <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>), compared with weak inhibitors of serotonin reuptake (eg, agomelatine, <a class="drug drug_general" data-topicid="9329" href="/d/drug information/9329.html" rel="external">desipramine</a>, and <a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">nortriptyline</a>) [<a href="#rid78">78</a>].</p><p>Bleeding may be associated with antidepressants other than SSRIs, which supports the idea that depression rather than SSRIs is associated with bleeding:</p><p class="bulletIndent1"><span class="glyph">●</span>A prospective observational study of individuals who underwent baseline brain imaging and subsequent imaging after a mean of four years (n &gt;2100) found that the risk of asymptomatic, subclinical cerebral bleeding between scans was comparable in individuals who used SSRIs or non-SSRI antidepressants between scans [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study (n &gt;4,000,000 patients) that found the risk of intracranial hemorrhage was higher with antidepressants plus NSAIDs compared with antidepressants alone, the increased risk was comparable in patients treated with SSRIs, SNRIs, or tricyclics [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study identified patients who received new prescriptions for an SSRI (n &gt;200,000) or an SNRI (n &gt;50,000); after using propensity scores to match the two groups on baseline characteristics (eg, age, sex, and comorbidities), the analyses found that the risk of nonfatal stroke was greater with SNRIs than SSRIs (hazard ratio 1.2, 95% CI 1.1-1.3) [<a href="#rid91">91</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A systematic review evaluated bleeding with <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a> and <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a>, which have relatively low affinity for the serotonin transporter and are weak inhibitors of serotonin reuptake [<a href="#rid92">92</a>]. As part of the review, a meta-analysis of five studies found that the risk of bleeding in patients treated with either SSRIs or mirtazapine (total n &gt;60,000) was comparable. Likewise, a meta-analysis of three studies found that the risk of bleeding in patients treated with either SSRIs or bupropion (total n &gt;14,000) was comparable.</p><p></p><p>The association between exposure to SSRIs and postpartum hemorrhage is discussed separately. (See  <a class="medical medical_review" href="/d/html/89067.html" rel="external">"Antenatal use of antidepressants and the potential risk of teratogenicity and adverse pregnancy outcomes: Selective serotonin reuptake inhibitors", section on 'Postpartum hemorrhage'</a>.)</p><p class="headingAnchor" id="H176537802"><span class="h3">Upper gastrointestinal bleeding</span><span class="headingEndMark"> — </span>Although SSRIs are associated with an elevated risk of upper gastrointestinal bleeding, the absolute risk is small and on par with the risk of bleeding in patients taking low doses of NSAIDs [<a href="#rid93">93</a>]. However, the likelihood of upper gastrointestinal hemorrhage is greater in patients with risk factors such as older age (eg, &gt;65 years); smoking or alcohol consumption; use of NSAIDs, other antiplatelet agents (eg, <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>), or anticoagulants (eg, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>); thrombocytopenia; platelet dysfunction (eg, von Willebrand disease); liver cirrhosis with coagulopathy; and prior history of upper gastrointestinal bleeding [<a href="#rid84">84,93</a>].</p><p>Meta-analyses of observational studies suggest that SSRIs are associated with upper gastrointestinal bleeding [<a href="#rid84">84,86,94</a>]; however, the absolute effect is low [<a href="#rid93">93,95</a>]. As an example:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis 15 observational studies identified patients who developed upper gastrointestinal bleeding and controls who did not (total n &gt;390,000) [<a href="#rid96">96</a>]. Treatment with SSRIs was more likely in patients with bleeding than controls (odds ratio 1.7, 95% CI 1.4-1.9). In addition, the study estimated that among low-risk patients (eg, no prior history of upper gastrointestinal bleeding), the number needed to harm was 3177. This means that on average, for every 3177 patients treated with SSRIs and every 3177 patients not treated with SSRIs, one additional episode of bleeding occurred with SSRIs. Among high-risk patients (eg, prior history of upper gastrointestinal bleeding), the number needed to harm was 881. The study also found that the risk of bleeding was further elevated with use of SSRIs plus NSAIDs (odds ratio 4.3, 95% CI 2.8-6.4).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another meta-analysis compared the risk of upper gastrointestinal bleeding in SSRI users with the risk in non-SSRI users, pooling data from 22 observational studies (n &gt;1,000,000 individuals, including more than 56,000 cases of bleeding) [<a href="#rid97">97</a>]. Exposure to SSRIs was associated with an increased risk of bleeding (odds ratio 1.6, 95% CI 1.4-1.8). The risk was even greater in the subgroup of patients who took SSRIs plus NSAIDs (odds ratio 3.7, 95% CI 3.0-4.7). By contrast, a separate subgroup analysis found that the risk of bleeding was comparable for patients who took SSRIs plus NSAIDs plus acid suppressing drugs and for patients who were not exposed to SSRIs.</p><p></p><p>Based upon these findings, some clinicians use non-SSRI antidepressants in patients at high risk for bleeding (eg, prior history of upper gastrointestinal bleeding), or prescribe a proton pump inhibitor when SSRIs are used in conjunction with NSAIDs; however, this is not standard practice.</p><p>Although SSRIs are often temporarily withheld in patients with peptic ulcer bleeding, doing so may not be necessary. A national registry study identified patients hospitalized for peptic ulcer bleeding who were using SSRIs (n &gt;1800) or were not (n &gt;12,000) [<a href="#rid98">98</a>]. After adjusting for potential confounding factors (eg, alcohol consumption, use of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> or anticoagulants, and American Society of Anesthesiologists physical status classification), the analyses showed that endoscopy-refractory bleeding, rebleeding, and 30-day mortality were each comparable in the two groups.</p><p class="headingAnchor" id="H3530422971"><span class="h3">Perioperative bleeding</span><span class="headingEndMark"> — </span>Although SSRIs may be associated with perioperative bleeding, the evidence is weak at best and the clinical relevance is unknown [<a href="#rid84">84</a>]. Thus, we suggest that clinicians should generally not stop SSRIs prior to surgery.</p><p>Multiple studies suggest that SSRIs may perhaps be associated with a marginally increased risk of perioperative bleeding. As an example, a meta-analysis of eight observational studies examined perioperative bleeding in patients who underwent different types of surgery and were either taking SSRIs prior to surgery or were not (total n &gt;560,000) [<a href="#rid99">99</a>]. Transfusion rates were modestly higher in patients taking SSRIs than controls (odds ratio 1.2, 95% CI 1.1-1.3). However, reoperation for a bleeding event was comparable in the two groups.</p><p>Subsequent studies have failed to find an association between SSRIs and perioperative bleeding. A retrospective study identified patients who underwent cardiac surgery, including patients who were taking SSRIs or SNRIs at the time of surgery, and controls who were not (total n &gt;1400) [<a href="#rid100">100</a>]. The two groups were matched for potentially confounding factors, including age, type of operation, and preoperative hemoglobin and platelet count. Postoperative bleeding was defined as chest tube output and reoperation for bleeding, each of which was comparable for patients treated with SSRIs/SNRIs and controls. Transfusion rates were also comparable for the two groups.</p><p class="headingAnchor" id="H99251864"><span class="h3">Stroke</span><span class="headingEndMark"> — </span>Although meta-analyses of observational studies suggest that SSRIs are associated with new onset stroke [<a href="#rid81">81</a>], the clinical significance of these findings is not clear because the magnitude of the increased risk is small [<a href="#rid85">85</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 16 studies that compared patients who received SSRIs with controls who did not (total n &gt;500,000), the risk of intracranial hemorrhage was elevated (relative risk 1.7, 95% CI 1.2-3.0) [<a href="#rid89">89</a>]. However, heterogeneity across studies was moderate, and the absolute risk of any stroke in patients using SSRIs was thought to be very low; it was estimated that SSRIs may lead to one additional intracerebral hemorrhage for every 10,000 patients treated for one year [<a href="#rid81">81,89,101</a>]. In addition, SSRI use was associated with a trend toward a protective effect against subarachnoid hemorrhage (relative risk 0.6, 95% CI 0.4-1.0).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second meta-analysis included four studies that controlled for confounding by depression and compared SSRI users with nonusers (total n &gt;13,000) [<a href="#rid102">102</a>]. The risk of stroke was greater in SSRI users, but the magnitude of the increased risk was small (odds ratio 1.2, 95% CI 1.1-1.3). These results are similar to a third meta-analysis that compared SSRI users with nonusers (eight studies, sample size not reported), which found that SSRIs were associated with a marginally increased risk of intracerebral hemorrhage (odds ratio 1.16, 95% CI 1.01-1.33) [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent retrospective study of an administrative health care dataset identified new users of antidepressants without a history of stroke, including patients who eventually suffered an intracranial hemorrhage (n &gt;3000) and controls who did not (n &gt;89,000); the two groups were matched for age, sex, and duration of follow-up [<a href="#rid78">78</a>]. After adjusting for potentially confounding factors (eg, alcohol abuse, smoking, and general medical comorbidities), the analyses found that the risk of intracranial hemorrhage was marginally greater with SSRIs than tricyclics (relative risk 1.17, 95% CI 1.02-1.35).</p><p></p><p>However, other studies suggest that the relative risk of stroke with SSRIs may be higher. As an example, an eight-year, retrospective study of an administrative health care dataset included patients who were exposed to SSRIs (n &gt;14,000) or were not (n &gt;394,000) [<a href="#rid103">103</a>]. After adjusting for potentially confounding factors such as age, sex, and diseases comorbid with stroke, the analyses found that the risk of stroke was more than twice as great among SSRI users (hazard ratio 2.6, 95% CI 2.4-2.7).</p><p>Multiple studies suggest that the association between SSRIs and stroke may be greatest relatively early during SSRI treatment, such as the first 30 days [<a href="#rid78">78</a>] or the first three years [<a href="#rid103">103</a>].</p><p>Aside from strokes, SSRIs may also be associated with asymptomatic, subclinical cerebral bleeding (microbleeds). A prospective observational study used magnetic resonance imaging to identify individuals with no prior history of microbleeds (n &gt;2100, age ≥45 years); brain imaging was repeated after a mean of four years, and use of SSRIs between scans was assessed [<a href="#rid90">90</a>]. After adjusting for the probability (propensity) of SSRI use between scans and for potential confounders observed at baseline, the analyses showed first-time microbleeds were more likely to occur in SSRI users than nonusers (odds ratio 2.4, 95% CI 1.1-5.3). However, reverse causality may explain the association, such that microbleeds may lead to psychiatric symptoms and use of SSRIs.</p><p>Multiple randomized trials in patients with a recent stroke have evaluated the benefit of SSRIs for functional outcomes. (See  <a class="medical medical_review" href="/d/html/1126.html" rel="external">"Initial assessment and management of acute stroke", section on 'Ischemic stroke management'</a>.)</p><p class="headingAnchor" id="H307447091"><span class="h4">Recurrence of stroke</span><span class="headingEndMark"> — </span>Use of SSRIs in patients with a prior history of stroke may be associated with an increased risk of recurrence of stroke. One prospective observational study enrolled patients who survived an intracerebral hemorrhage (n &gt;1200) and followed them for a median of 53 months [<a href="#rid104">104</a>]. After adjusting for potentially confounding factors (eg, education, location of prior intracerebral hemorrhage, and apolipoprotein E genotype), the analyses showed that recurrence of intracerebral hemorrhage was modestly greater in SSRI users than nonusers (hazard ratio 1.3, 95% CI 1.1-1.6). In addition, the association between SSRIs and recurrence was greater in patients at high risk of recurrence (eg, prior history of hemorrhages) compared with non-high-risk patients, and was greater in patients treated with high doses of SSRIs than low doses.</p><p class="headingAnchor" id="H175306181"><span class="h4">Mortality after stroke</span><span class="headingEndMark"> — </span>Most evidence suggests that SSRIs do not increase the risk of death in patients with strokes:</p><p class="bulletIndent1"><span class="glyph">●</span>Among patients who use SSRIs and subsequently suffer a stroke, it is not clear whether SSRIs are associated with increased mortality due to contradictory results across observational studies:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A prospective, five-year study of patients who suffered a stroke included patients who were taking an SSRI at the time of the stroke (n = 55) and patients who were not (n = 1082) [<a href="#rid105">105</a>]. Mortality in the two groups was comparable. However, depression three months after the stroke was associated with an increased risk of death (hazard ratio 1.4, 95% CI 1.1-1.7).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A national registry study identified patients who had suffered hemorrhagic strokes and used SSRIs in the 90 days before the stroke (n = 626), and patients with strokes who had not used SSRIs (n = 626) [<a href="#rid106">106</a>]. Propensity scoring was used to match the two groups with regard to observed potential confounders (eg, age, sex, history of general medical illnesses, and exposure to other medications). Prestroke SSRI use was associated with an elevated risk of death in the 30 days after the stroke (odds ratio 1.6, 95% CI 1.2-2.2).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Based upon randomized trials, the risk of death is not increased in patients who suffer a stroke and are subsequently treated with SSRIs. As an example, a meta-analysis of 46 trials compared SSRIs with control conditions in patients who suffered strokes (n &gt;3000) [<a href="#rid82">82,83</a>]. Mortality was comparable in the two groups.</p><p></p><p class="headingAnchor" id="H512804756"><span class="h2">Hyponatremia</span><span class="headingEndMark"> — </span>SSRIs are associated with the syndrome of inappropriate antidiuretic hormone secretion and hyponatremia, but the absolute rate is low [<a href="#rid1">1-4,107</a>]. Risk factors include older age (eg, &gt;65 years), concurrent diuretics, and prior history of hyponatremia [<a href="#rid107">107-109</a>]. The literature emphasizes the increased morbidity that can occur with serum sodium concentrations below 135 mmol/L, such as instability and falls, reduced cognitive function, and osteoporosis; mortality is also increased [<a href="#rid110">110</a>].</p><p class="bulletIndent1">Medications with any risk of hyponatremia are concerning in patients with prior hyponatremia [<a href="#rid107">107</a>]. In currently depressed patients with a history of hyponatremia from any cause, who are starting an SSRI, we suggest obtaining sodium levels at baseline and again two weeks afterwards, because if hyponatremia occurs, it is likely to occur early. One study that examined the association between antidepressants and hyponatremia found that the risk of hyponatremia was greatest within the first two weeks of treatment [<a href="#rid109">109,110</a>]. Another study found that among psychiatric inpatients who developed hyponatremia attributed solely to SSRIs, the median time to onset was 11 days [<a href="#rid108">108</a>], and a third study found that paroxetine-induced hyponatremia in older adult patients occurred within a mean of 9 days [<a href="#rid109">109</a>].</p><p></p><p>Retrospective studies suggest that SSRIs are strongly associated with hyponatremia:</p><p class="bulletIndent1"><span class="glyph">●</span>In a registry study that included more than 600,000 patients, SSRIs were prescribed to more than 93,000 patients; hyponatremia was defined as a serum sodium level &lt;135 mmol/L [<a href="#rid110">110</a>]. After adjusting for potentially confounding factors such as age, comorbid illnesses, and concurrent pharmacotherapy, the analyses found that two weeks after SSRIs were initiated, hyponatremia was far more likely to occur in patients treated with SSRIs than patients who received no antidepressant (incidence rate ratio 8.7, 95% CI 8.9-9.5). The incidence rate ratio (95% CI) for the association between each specific SSRI and hyponatremia was as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> – 7.8 (7.4-8.2)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">Escitalopram</a> – 3.7 (3.3-4.2)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">Fluoxetine</a> – 5.6 (4.5-7.0)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">Paroxetine</a> – 6.2 (5.3-7.2)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">Sertraline</a> – 4.5 (4.0-5.1)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another registry study identified patients with a first-ever hospitalization for hyponatremia (cases; n &gt;14,000) and controls matched for age and sex with no lifetime history of hyponatremia (n &gt;57,000); hyponatremia was defined as a serum sodium level &lt;135 mmol/L [<a href="#rid111">111,112</a>]. Newly initiated treatment with an SSRI was far more likely to have occurred in the cases hospitalized for hyponatremia than in controls, as indicated by the following odds ratios (95% CI):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> – 6.5 (5.4-7.8)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">Escitalopram</a> – 3.0 (1.8-5.1)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">Sertraline</a> – 6.8 (5.0-9.3)</p><p class="bulletIndent2"><span class="glyph">•</span>Other SSRIs – 4.5 (2.2-9.2)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of administrative health care databases identified two groups of individuals older than 65 years: patients with depressive or anxiety disorders who received a new prescription for an SSRI or another second-generation antidepressant, and controls who did not start an antidepressant (n &gt;138,000 in each group) [<a href="#rid107">107</a>]. The two groups were matched on the probability (propensity) of receiving an antidepressant and on potentially confounding factors such as sex, general medical disorders, and pharmacotherapy. Hospitalization for hyponatremia occurred in far more SSRI users than controls, as indicated by the following risk ratios (95% CI):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> – 5.8 (4.1-8.0)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">Escitalopram</a> – 4.8 (2.6-8.7)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">Paroxetine</a> – 8.0 (3.7-17.6)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">Sertraline</a> – 7.3 (3.3-16.1)</p><p></p><p>However, the absolute rate of hyponatremia associated with SSRIs is low (which means large samples are required to estimate the risk). In addition, rates vary with the study population, definition of hyponatremia (eg, hospitalization or serum sodium &lt;130 mmol/L or &lt;135 mmol/L), and with the length of exposure [<a href="#rid109">109</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A drug surveillance program of psychiatric inpatients found that among those treated with SSRIs (n &gt;50,000), hyponatremia (serum sodium &lt;130 mmol/L) occurred in 0.06 percent [<a href="#rid108">108</a>]. Among patients who received an SSRI plus an angiotensin converting enzyme inhibitor (n &gt;4000), the rate of hyponatremia was 4.5 times larger (0.27 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study of administrative health care databases identified two groups of individuals older than 65 years: patients who received a new prescription for an SSRI or another second-generation antidepressant, and controls who did not start an antidepressant (n &gt;138,000 in each group) [<a href="#rid107">107</a>]. The two groups were matched on the probability (propensity) of receiving an antidepressant and on potentially confounding factors observed at baseline. Hospitalization for hyponatremia occurred in more antidepressant users than controls (0.33 versus 0.06 percent).</p><p></p><p class="headingAnchor" id="H3798932435"><span class="h2">Other</span><span class="headingEndMark"> — </span>The literature suggests that SSRIs may possibly be associated with other adverse effects. However, the evidence often consists of low-quality studies with small effect sizes, and the results should generally not deter clinicians from using SSRIs when indicated:</p><p class="bulletIndent1"><span class="glyph">●</span>Bone fractures – Many observational studies have found an association between SSRI use and bone fractures. (See  <a class="medical medical_review" href="/d/html/2036.html" rel="external">"Drugs that affect bone metabolism", section on 'Antidepressants'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ophthalmic</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cataracts – Exposure to SSRIs is marginally associated with developing cataracts [<a href="#rid113">113</a>]. As an example, a meta-analysis of seven observational studies included patients with cataracts (n &gt;400,000) and controls without cataracts (n &gt;1,500,000) [<a href="#rid114">114</a>]. Use of SSRIs was slightly greater in cataract patients than controls (odds ratio 1.12, 95% CI 1.06-1.19).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Glaucoma – A meta-analysis of seven observational studies, which included SSRI users (n &gt;160,000) and nonusers (630,000), found that after adjusting for potentially confounding factors (eg, age, general medical disorders, eye diseases, and depressive symptoms), the risk of glaucoma was comparable for the two groups, suggesting that SSRIs do not cause glaucoma [<a href="#rid115">115</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Seizures – The risk of seizures with SSRIs is low and may be reduced compared with placebo [<a href="#rid116">116</a>]. However, seizures may occur with large overdoses. In addition, some SSRIs can increase serum levels of concomitant medicines, which may secondarily increase the risk of seizures. (See <a class="local">'Drug-drug interactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Violent behavior – A national registry study included more than 780,000 patients who were treated with an SSRI, and compared the rate of conviction for violent crime (eg, manslaughter, harassment, and assault) during periods on versus off treatment with the SSRI; the mean follow-up time was seven years [<a href="#rid117">117</a>]. After adjusting for potentially confounding factors (sex, lifetime diagnoses, and history of violent crime), the analyses found a nominal association between current use of SSRIs and violent crime conviction (hazard ratio 1.10; 95% CI 1.06-1.13) [<a href="#rid117">117</a>]. However, the observed association between SSRI exposure and violent behavior may be confounded because the disorders that were treated with SSRIs are also associated with violent behavior (confounding by indication).</p><p></p><p class="headingAnchor" id="H4082148901"><span class="h1">EFFICACY FOR MAJOR DEPRESSION</span><span class="headingEndMark"> — </span>The efficacy of selective serotonin reuptake inhibitors for treating unipolar major depression is discussed separately in the context of choosing a regimen for the initial treatment of major depression and for treatment-resistant depression. (See  <a class="medical medical_review" href="/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment"</a> and  <a class="medical medical_review" href="/d/html/14685.html" rel="external">"Unipolar depression in adults: Choosing treatment for resistant depression"</a>.)</p><p class="headingAnchor" id="H3662563341"><span class="h1">OVERDOSE</span><span class="headingEndMark"> — </span>A single-substance selective serotonin reuptake inhibitor (SSRI) overdose rarely causes death or serious sequelae. SSRIs (except for <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> and <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a>) have a wide therapeutic window, such that overdoses of up to 30 times the usual daily dose typically produce minor or no symptoms, while larger ingestions may cause drowsiness, tremor, and vomiting. Nearly all fatalities from SSRI overdoses involve extremely large doses or coingestion of other substances. A rapid overview of the clinical features and management of SSRI overdoses is provided in the table  (<a class="graphic graphic_table graphicRef82567" href="/d/graphic/82567.html" rel="external">table 5</a>). Additional information about acute poisoning from SSRIs is reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/297.html" rel="external">"Selective serotonin reuptake inhibitor poisoning"</a>.)</p><p>Among different SSRIs, relatively low-quality evidence suggests that <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> may be more lethal in overdose than other SSRIs [<a href="#rid118">118</a>]. A retrospective study examined reports to the United States Poison Control Centers that included exposures to SSRIs (n &gt;180,000) over a 15-year period [<a href="#rid119">119</a>]. The mortality risk per 10,000 exposures was three times greater for citalopram than <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, and five times greater for citalopram than <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a>, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, and <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>. The increased fatality observed with citalopram may be related to dose-dependent QT prolongation. (See <a class="local">'Citalopram'</a> above.)</p><p class="headingAnchor" id="H517241"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16338.html" rel="external">"Patient education: Coping with high drug prices (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/4866.html" rel="external">"Patient education: Depression treatment options for adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/4868.html" rel="external">"Patient education: Depression in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/16279.html" rel="external">"Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"</a>)</p><p></p><p>The National Institute of Mental Health also has educational material on the use of antidepressants, including SSRIs, entitled, "What medications are used to treat depression?" that is available online at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nimh.nih.gov%2Fhealth%2Ftopics%2Fmental-health-medications&amp;token=DUyqmXMqVzfwMQwHS0hGhjVnvSmWNYwrVIOQjil9H1c7QeKzCSx0qXlroHThkaY5AZSlsPjqMvW2SrhzIcY0ie182z2bJyFkd3seZ7M6%2Fa0%3D&amp;TOPIC_ID=14675" target="_blank">the website</a>. Material explaining the symptoms, causes, and treatment for depression is also available in a booklet entitled "Depression" that is available online at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nimh.nih.gov%2Fhealth%2Fpublications%2Fdepression&amp;token=lblfowwGB6QwC91WNuiIf4ajjCUnrtrjbsV3PkfR7znk0D5d%2Fr0ErMPgiqIitkwYLP%2FHA1tFvsLfSIGbbHxrmA%3D%3D&amp;TOPIC_ID=14675" target="_blank">the website</a>. Both publications can also be obtained through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.</p><p>The Depression and Bipolar Support Alliance (available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.dbsalliance.org%2F&amp;token=ZAuWdG5s4GIvjFnkWRP6rC6dBWU8%2FMZEcwGeeAm5c58EpMgcvhu2s4%2FQc68YQejm&amp;TOPIC_ID=14675" target="_blank">the website</a> or 800-826-3632) is a national organization whose mission is to educate members about depressive and bipolar disorders and how to cope with them. Other functions include increasing public awareness of the illnesses and advocating for more research and services. The organization has local chapters and is administered and maintained by patients and family members.</p><p>The National Alliance on Mental Illness (available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nami.org%2FHome&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F8kABYN690CzsdrTBuRq2QekIBbQQeqX70Vmx%2B0z8d0m&amp;TOPIC_ID=14675" target="_blank">the website</a> or 800-950-6264) is a similarly structured organization devoted to providing education, support, and advocacy for patients with any mental illness. Depression is one of their priorities.</p><p class="headingAnchor" id="H399779858"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific drugs and indications </strong>– The selective serotonin reuptake inhibitors (SSRIs) include <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a>, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a>, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, and <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>. SSRIs are frequently first-line agents for depressive disorders because of their efficacy, tolerability, and general safety in overdose. Other indications include anxiety disorders, eating disorders, obsessive-compulsive and related disorders, and posttraumatic stress disorder. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacodynamics</strong> – SSRIs inhibit the serotonin reuptake pump and increase postsynaptic serotonin receptor occupancy. This initial action may cause subsequent changes involved in treating depression. SSRIs are selective in that they have relatively little affinity for other types of receptors, although they have secondary effects on neurotransmission involving norepinephrine and dopamine. (See <a class="local">'Pharmacodynamics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoiding drug-drug interactions</strong> – The SSRIs may inhibit hepatic cytochrome P450 enzymes that metabolize other medications and cause drug-drug interactions. <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> and <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> inhibit liver enzymes less than other SSRIs and are usually the SSRIs of choice for situations in which drug-drug interactions are a concern. (See <a class="local">'Drug-drug interactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – SSRIs should generally be started at their minimal effective dose  (<a class="graphic graphic_table graphicRef53818" href="/d/graphic/53818.html" rel="external">table 2</a>). A process of trial and error is used to find the effective dose. Dose adjustments are made according to patient response, tolerability, and clinical urgency.</p><p></p><p class="bulletIndent1">For <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>, the maximum dose is nearly always 40 mg/day because of dose-dependent QT interval prolongation. In addition, the recommended maximum dose is 20 mg/day in patients with risk factors for increased serum concentrations, including hepatic impairment and age &gt;60 years. Citalopram should be avoided in patients with congenital long QT syndrome, persistent corrected QT measurements &gt;500 milliseconds, bradycardia, hypokalemia, hypomagnesemia, recent myocardial infarction, or uncompensated heart failure, as well as patients taking other drugs that prolong the QT interval. (See <a class="local">'Dose'</a> above and <a class="local">'Cardiac'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Side effects</strong> – Common SSRI side effects  (<a class="graphic graphic_table graphicRef62488" href="/d/graphic/62488.html" rel="external">table 3</a>) include nausea, dry mouth, headache, insomnia, loose stools, sexual dysfunction, somnolence, sweating, tremor, and weight change. In addition, SSRIs may increase the risk of bleeding, bone fractures, dizziness, extrapyramidal symptoms, and hyponatremia. (See <a class="local">'Side effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overdose</strong> – A single-substance SSRI overdose rarely causes death or serious sequelae. Except for <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> and <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a>, overdoses of SSRIs of up to 30 times the usual daily dose typically produce minor or no symptoms. Nearly all fatalities from SSRI overdoses involve extremely large doses or coingestion of other substances. (See <a class="local">'Overdose'</a> above.)</p><p></p><p class="bulletIndent1">A rapid overview of the clinical features and management of SSRI overdoses is provided in the table  (<a class="graphic graphic_table graphicRef82567" href="/d/graphic/82567.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/d/html/297.html" rel="external">"Selective serotonin reuptake inhibitor poisoning"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Rosenbaum JF, Ionescu DF. Fluoxetine. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.335.</li><li class="breakAll">Roseboom, PH, Kalin, NH. Citalopram and escitalopram. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.431.</li><li class="breakAll">Howlett JR, Stein MB, Nemeroff CB. Paroxetine. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.385.</li><li class="breakAll">Carpenter LL, Schatzberg AF. Sertraline. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.359.</li><li class="breakAll">Aboujaoude E, Koran LM. Fluvoxamine. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.419.</li><li><a class="nounderline abstract_t">Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008; 455:894.</a></li><li><a class="nounderline abstract_t">Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32 Suppl 1:1.</a></li><li class="breakAll">MedicinesComplete [Internet database]. Pharmaceutical Press, London, 2010 http://www.medicinescomplete.com (Accessed on September 28, 2010).</li><li class="breakAll">DRUGDEX® System [Internet database]. Greenwood Village, CO, Thomson Reuters (Healthcare) Inc, 2002-2010. (Accessed September 28, 2010).</li><li class="breakAll">Wynn, GH, Sandson, et al. Psychiatry. In: Clinical Manual of Drug Interaction Principles for Medical Practice, Wynn, GH, Oesterheld, JR, Cozza, KL, Armstrong, SC (Eds), American Psychiatric Publishing, Inc, Washington, D.C. 2009. p.423.</li><li class="breakAll">Treatment Guidelines from The Medical Letter. The Medical Letter, Volume 8, (Issue 93), May, 2010, p. 35.</li><li class="breakAll">Labbate, LA, Fava, et al. Drugs for the treatment of depression. In: Handbook of Psychiatric Drug Therapy, 6th ed, Lippincott Williams &amp; Wilkins, Philadelphia, PA 2010. p.54.</li><li><a class="nounderline abstract_t">Parthipan A, Banerjee I, Humphreys K, et al. Predicting inadequate postoperative pain management in depressed patients: A machine learning approach. PLoS One 2019; 14:e0210575.</a></li><li><a class="nounderline abstract_t">Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51:9.</a></li><li><a class="nounderline abstract_t">Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 2006; 63:1217.</a></li><li><a class="nounderline abstract_t">Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 2000; 157:1423.</a></li><li><a class="nounderline abstract_t">Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28.</a></li><li><a class="nounderline abstract_t">Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther 2015; 98:127.</a></li><li><a class="nounderline abstract_t">Furukawa TA, Cipriani A, Cowen PJ, et al. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry 2019; 6:601.</a></li><li><a class="nounderline abstract_t">Hieronymus F. Which antidepressant doses are optimal? Lancet Psychiatry 2019; 6:552.</a></li><li><a class="nounderline abstract_t">Jakubovski E, Varigonda AL, Freemantle N, et al. Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. Am J Psychiatry 2016; 173:174.</a></li><li class="breakAll">Chew RH. Psychiatric medications. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.1631.</li><li class="breakAll">Sadock BJ, Sadock VA, Ruiz P. Mood disorders. In: Kaplan &amp; Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry, Eleventh Edition, Wolters Kluwer, Philadelphia, PA 2015. p.347.</li><li class="breakAll">Levenson JL, Crouse EL, Bozymski KM. Psychopharmacology. In: The American Psychiatric Association Publishing Textbook of Psychiatry, Seventh Edition, Roberts LW (Ed), American Psychiatric Association Publishing, Washington, DC 2019. p.791.</li><li class="breakAll">FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). August 24, 2011. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-associated-high-doses-celexa-citalopram (Accessed on August 26, 2020).</li><li class="breakAll">FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. March 28, 2012. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related (Accessed on August 26, 2020).</li><li><a class="nounderline abstract_t">Jefferson JW. Caring for the Patient. J Clin Psychiatry 2017; 78:e166.</a></li><li><a class="nounderline abstract_t">Funk MC, Beach SR, Bostwick JR, et al. QTc Prolongation and Psychotropic Medications. Am J Psychiatry 2020; 177:273.</a></li><li><a class="nounderline abstract_t">Omori IM, Watanabe N, Nakagawa A, et al. Fluvoxamine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2010; :CD006114.</a></li><li><a class="nounderline abstract_t">Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 2013; 14:334.</a></li><li><a class="nounderline abstract_t">Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry 2016; 61:540.</a></li><li><a class="nounderline abstract_t">Nierenberg AA, Ostacher MJ, Huffman JC, et al. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. J Occup Environ Med 2008; 50:428.</a></li><li><a class="nounderline abstract_t">Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004; 65:959.</a></li><li><a class="nounderline abstract_t">Jimenez-Jimenez FJ, Molina JA. Extrapyramidal symptoms associated with selective serotonin reuptake inhibitors. CNS Drugs 2000; 14:367.</a></li><li><a class="nounderline abstract_t">Cipriani A, La Ferla T, Furukawa TA, et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev 2010; :CD006117.</a></li><li><a class="nounderline abstract_t">Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. Am J Psychiatry 2007; 164:1786.</a></li><li><a class="nounderline abstract_t">Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. N Engl J Med 2007; 356:2343.</a></li><li class="breakAll">Owen JA, Crouse EL, Kirkwood CK, Levenson JL. Psychopharmacology. In: The American Psychiatric Association Publishing Textbook of Psychosomatic Medicine and Consultation-Liaison Psyhciatry, Third Edition, Levenson JL (Ed), American Psychiatric Association Publishing, Washington, DC 2019. p.1181.</li><li><a class="nounderline abstract_t">Beach SR, Kostis WJ, Celano CM, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry 2014; 75:e441.</a></li><li><a class="nounderline abstract_t">Coupland C, Hill T, Morriss R, et al. Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database. BMJ 2016; 352:i1350.</a></li><li><a class="nounderline abstract_t">Oh SW, Kim J, Myung SK, et al. Antidepressant use and risk of coronary heart disease: meta-analysis of observational studies. Br J Clin Pharmacol 2014; 78:727.</a></li><li><a class="nounderline abstract_t">Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs 2014; 28:887.</a></li><li><a class="nounderline abstract_t">Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 2014; 311:682.</a></li><li><a class="nounderline abstract_t">Girardin FR, Gex-Fabry M, Berney P, et al. Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study. Am J Psychiatry 2013; 170:1468.</a></li><li><a class="nounderline abstract_t">Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013; 346:f288.</a></li><li><a class="nounderline abstract_t">Vieweg WV, Hasnain M, Howland RH, et al. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? Am J Med 2012; 125:859.</a></li><li><a class="nounderline abstract_t">Zivin K, Pfeiffer PN, Bohnert AS, et al. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry 2013; 170:642.</a></li><li><a class="nounderline abstract_t">Rector TS, Adabag S, Cunningham F, et al. Outcomes of Citalopram Dosage Risk Mitigation in a Veteran Population. Am J Psychiatry 2016; 173:896.</a></li><li><a class="nounderline abstract_t">Ray WA, Chung CP, Murray KT, et al. High-Dose Citalopram and Escitalopram and the Risk of Out-of-Hospital Death. J Clin Psychiatry 2017; 78:190.</a></li><li><a class="nounderline abstract_t">Bird ST, Crentsil V, Temple R, et al. Cardiac safety concerns remain for citalopram at dosages above 40 mg/day. Am J Psychiatry 2014; 171:17.</a></li><li><a class="nounderline abstract_t">Zivin K, Pfeiffer PN, Bohnert AS, et al. Safety of high-dosage citalopram. Am J Psychiatry 2014; 171:20.</a></li><li><a class="nounderline abstract_t">Thase ME, Larsen KG, Reines E, Kennedy SH. The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol 2013; 23:1391.</a></li><li><a class="nounderline abstract_t">Hanash JA, Hansen BH, Hansen JF, et al. Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial. J Cardiovasc Pharmacol 2012; 60:397.</a></li><li><a class="nounderline abstract_t">Van Asbroeck PJ, Huybrechts W, De Soir R. Case report, aetiology, and treatment of an acquired long-QT syndrome. Acta Clin Belg 2014; 69:132.</a></li><li><a class="nounderline abstract_t">Tseng PT, Lee Y, Lin YE, Lin PY. Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature review. Gen Hosp Psychiatry 2012; 34:210.e13.</a></li><li><a class="nounderline abstract_t">Ramaswamy S, Selvaraj V, Driscoll D, et al. Effects of Escitalopram on Autonomic Function in Posttraumatic Stress Disorder Among Veterans of Operations Enduring Freedom and Iraqi Freedom (OEF/OIF). Innov Clin Neurosci 2015; 12:13.</a></li><li><a class="nounderline abstract_t">Chung H, Kim A, Lim KS, et al. Pharmacokinetics and effect on the corrected QT interval of single-dose escitalopram in healthy elderly compared with younger adults. Int Clin Psychopharmacol 2017; 32:20.</a></li><li><a class="nounderline abstract_t">Ojero-Senard A, Benevent J, Bondon-Guitton E, et al. A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology (Berl) 2017; 234:3075.</a></li><li><a class="nounderline abstract_t">Sylvester C, Menke M, Gopalan P. Selective Serotonin Reuptake Inhibitors and Fertility: Considerations for Couples Trying to Conceive. Harv Rev Psychiatry 2019; 27:108.</a></li><li><a class="nounderline abstract_t">Maina G, Albert U, Salvi V, Bogetto F. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry 2004; 65:1365.</a></li><li><a class="nounderline abstract_t">Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999; 156:1170.</a></li><li><a class="nounderline abstract_t">Croft H, Settle E Jr, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999; 21:643.</a></li><li><a class="nounderline abstract_t">Uher R, Farmer A, Henigsberg N, et al. Adverse reactions to antidepressants. Br J Psychiatry 2009; 195:202.</a></li><li><a class="nounderline abstract_t">de Jonghe F, Ravelli DP, Tuynman-Qua H. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry 1991; 24:62.</a></li><li><a class="nounderline abstract_t">Wade A, Michael Lemming O, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17:95.</a></li><li><a class="nounderline abstract_t">Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18:211.</a></li><li class="breakAll">Goldberg JF, Ernst CL. Metabolic dysregulation and weight gain. In: Managing the Side Effects of Psychotropic Medications, Second Edition, American Psychiatric Association Publishing, Washington, DC 2019. p.253.</li><li class="breakAll">Owen JA, Crouse EL, Kirkwood CK, Levenson JL. Psychopharmacology. In: The American Psychiatric Association Publishing Textbook of Psychosomatic Medicine and Consultation-Liaison Psychiatry, Third Edition, Levenson JL (Ed), American Psychiatric Association Publishing, Washington, DC 2019. p.1181.</li><li class="breakAll">Fireman M, DiMartini AF, Crone CC. Organ transplantation. In: Clinical Manual of Psychopharmacology in the Medically Ill, Second Edition, Levenson JL, Ferrando SJ (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.597.</li><li><a class="nounderline abstract_t">Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000; 61:863.</a></li><li><a class="nounderline abstract_t">Hochstrasser B, Isaksen PM, Koponen H, et al. Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry 2001; 178:304.</a></li><li><a class="nounderline abstract_t">Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997; 95:153.</a></li><li><a class="nounderline abstract_t">Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992; 160:217.</a></li><li><a class="nounderline abstract_t">Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61 Suppl 11:37.</a></li><li><a class="nounderline abstract_t">Secher A, Bukh J, Bock C, et al. Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1. Int Clin Psychopharmacol 2009; 24:199.</a></li><li><a class="nounderline abstract_t">Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009; 166:591.</a></li><li><a class="nounderline abstract_t">Hankey GJ. Selective serotonin reuptake inhibitors and risk of cerebral bleeding. Stroke 2014; 45:1917.</a></li><li><a class="nounderline abstract_t">Renoux C, Vahey S, Dell'Aniello S, Boivin JF. Association of Selective Serotonin Reuptake Inhibitors With the Risk for Spontaneous Intracranial Hemorrhage. JAMA Neurol 2017; 74:173.</a></li><li><a class="nounderline abstract_t">de Abajo FJ, García-Rodríguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65:795.</a></li><li><a class="nounderline abstract_t">Schalekamp T, Klungel OH, Souverein PC, de Boer A. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med 2008; 168:180.</a></li><li><a class="nounderline abstract_t">Hemphill JC 3rd. Selective Serotonin Reuptake Inhibitors and Intracranial Hemorrhage: Deriving Clinical Relevance From an Epidemiologic Association. JAMA Neurol 2017; 74:148.</a></li><li><a class="nounderline abstract_t">Mead GE, Hsieh CF, Lee R, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev 2012; 11:CD009286.</a></li><li><a class="nounderline abstract_t">Mead GE, Hsieh CF, Lee R, et al. Selective serotonin reuptake inhibitors for stroke recovery: a systematic review and meta-analysis. Stroke 2013; 44:844.</a></li><li><a class="nounderline abstract_t">Bixby AL, VandenBerg A, Bostwick JR. Clinical Management of Bleeding Risk With Antidepressants. Ann Pharmacother 2019; 53:186.</a></li><li><a class="nounderline abstract_t">Andrade C, Sharma E. Serotonin Reuptake Inhibitors and Risk of Abnormal Bleeding. Psychiatr Clin North Am 2016; 39:413.</a></li><li><a class="nounderline abstract_t">Laporte S, Chapelle C, Caillet P, et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies. Pharmacol Res 2017; 118:19.</a></li><li><a class="nounderline abstract_t">Labos C, Dasgupta K, Nedjar H, et al. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011; 183:1835.</a></li><li><a class="nounderline abstract_t">Shin JY, Park MJ, Lee SH, et al. Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study. BMJ 2015; 351:h3517.</a></li><li><a class="nounderline abstract_t">Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology 2012; 79:1862.</a></li><li><a class="nounderline abstract_t">Akoudad S, Aarts N, Noordam R, et al. Antidepressant Use Is Associated With an Increased Risk of Developing Microbleeds. Stroke 2016; 47:251.</a></li><li><a class="nounderline abstract_t">Leong C, Alessi-Severini S, Enns MW, et al. Cerebrovascular, Cardiovascular, and Mortality Events in New Users of Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors: A Propensity Score-Matched Population-Based Study. J Clin Psychopharmacol 2017; 37:332.</a></li><li><a class="nounderline abstract_t">Na KS, Jung HY, Cho SJ, Cho SE. Can we recommend mirtazapine and bupropion for patients at risk for bleeding?: A systematic review and meta-analysis. J Affect Disord 2018; 225:221.</a></li><li class="breakAll">Crone CC, Lackamp JM, Alkis AR. Gastrointestinal disorders. In: The American Psychiatric Association Publishing Textbook of Psychosomatic Medicine and Consultation-Liaison Psychiatry, Third Edition, Levenson JL (Ed), American Psychiatric Association Publishing, Washington, DC 2019. p.527.</li><li class="breakAll">United Kingdom National Health Service. March 2, 2015. http://www.medicinesresources.nhs.uk/getdocument.aspx?pageid=513145 (Accessed on March 27, 2015).</li><li><a class="nounderline abstract_t">Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010; 71:1565.</a></li><li><a class="nounderline abstract_t">Anglin R, Yuan Y, Moayyedi P, et al. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109:811.</a></li><li><a class="nounderline abstract_t">Jiang HY, Chen HZ, Hu XJ, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015; 13:42.</a></li><li><a class="nounderline abstract_t">Laursen SB, Leontiadis GI, Stanley AJ, et al. The use of selective serotonin receptor inhibitors (SSRIs) is not associated with increased risk of endoscopy-refractory bleeding, rebleeding or mortality in peptic ulcer bleeding. Aliment Pharmacol Ther 2017; 46:355.</a></li><li><a class="nounderline abstract_t">Singh I, Achuthan S, Chakrabarti A, et al. Influence of pre-operative use of serotonergic antidepressants (SADs) on the risk of bleeding in patients undergoing different surgical interventions: a meta-analysis. Pharmacoepidemiol Drug Saf 2015; 24:237.</a></li><li><a class="nounderline abstract_t">Smith MM, Smith BB, Lahr BD, et al. Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors Are Not Associated With Bleeding or Transfusion in Cardiac Surgical Patients. Anesth Analg 2018; 126:1859.</a></li><li><a class="nounderline abstract_t">McGrath ER, O'Donnell MJ. Estimating treatment effects in observational studies. Neurology 2012; 79:1844.</a></li><li><a class="nounderline abstract_t">Shin D, Oh YH, Eom CS, Park SM. Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and meta-analysis. J Neurol 2014; 261:686.</a></li><li><a class="nounderline abstract_t">Chan CH, Huang HH, Lin CH, et al. Risk of First Onset Stroke in SSRI-Exposed Adult Subjects: Survival Analysis and Examination of Age and Time Effects. J Clin Psychiatry 2017; 78:e1006.</a></li><li><a class="nounderline abstract_t">Kubiszewski P, Sugita L, Kourkoulis C, et al. Association of Selective Serotonin Reuptake Inhibitor Use After Intracerebral Hemorrhage With Hemorrhage Recurrence and Depression Severity. JAMA Neurol 2020.</a></li><li><a class="nounderline abstract_t">Ayerbe L, Ayis S, Crichton SL, et al. Explanatory factors for the increased mortality of stroke patients with depression. Neurology 2014; 83:2007.</a></li><li><a class="nounderline abstract_t">Mortensen JK, Larsson H, Johnsen SP, Andersen G. Impact of prestroke selective serotonin reuptake inhibitor treatment on stroke severity and mortality. Stroke 2014; 45:2121.</a></li><li><a class="nounderline abstract_t">Gandhi S, Shariff SZ, Al-Jaishi A, et al. Second-Generation Antidepressants and Hyponatremia Risk: A Population-Based Cohort Study of Older Adults. Am J Kidney Dis 2017; 69:87.</a></li><li><a class="nounderline abstract_t">Letmaier M, Painold A, Holl AK, et al. Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme. Int J Neuropsychopharmacol 2012; 15:739.</a></li><li><a class="nounderline abstract_t">Lien YH. Antidepressants and Hyponatremia. Am J Med 2018; 131:7.</a></li><li><a class="nounderline abstract_t">Leth-Møller KB, Hansen AH, Torstensson M, et al. Antidepressants and the risk of hyponatremia: a Danish register-based population study. BMJ Open 2016; 6:e011200.</a></li><li><a class="nounderline abstract_t">Farmand S, Lindh JD, Calissendorff J, et al. Differences in Associations of Antidepressants and Hospitalization Due to Hyponatremia. Am J Med 2018; 131:56.</a></li><li><a class="nounderline abstract_t">Farmand S, Lindh JD, Calissendorff J, et al. Corrigendum to "Differences in Associations of Antidepressants and Hospitalization Due to Hyponatremia" AmJMed, 131(01);56-63. Am J Med 2021; 134:554.</a></li><li><a class="nounderline abstract_t">Andrade C. Antidepressants, Mood Stabilizers, Antipsychotics, and the Risk of Cataract. J Clin Psychiatry 2019; 80.</a></li><li><a class="nounderline abstract_t">Fu Y, Dai Q, Zhu L, Wu S. Antidepressants use and risk of cataract development: a systematic review and meta-analysis. BMC Ophthalmol 2018; 18:31.</a></li><li><a class="nounderline abstract_t">Wang HY, Tseng PT, Stubbs B, et al. The risk of glaucoma and serotonergic antidepressants: A systematic review and meta-analysis. J Affect Disord 2018; 241:63.</a></li><li class="breakAll">Campbell EC, Caroff SN, Mann SC, et al. Severe drug reactions. In: Clinical Manual pf Psychopharmacology in the Medically Ill, Second Edition, Levenson JL, Ferrando SJ (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.45.</li><li><a class="nounderline abstract_t">Lagerberg T, Fazel S, Molero Y, et al. Associations between selective serotonin reuptake inhibitors and violent crime in adolescents, young, and older adults - a Swedish register-based study. Eur Neuropsychopharmacol 2020; 36:1.</a></li><li><a class="nounderline abstract_t">Marder SR, Gitlin MJ. A Cruel Irony for Clinicians Who Treat Depression. Am J Psychiatry 2017; 174:409.</a></li><li><a class="nounderline abstract_t">Nelson JC, Spyker DA. Morbidity and Mortality Associated With Medications Used in the Treatment of Depression: An Analysis of Cases Reported to U.S. Poison Control Centers, 2000-2014. Am J Psychiatry 2017; 174:438.</a></li></ol></div><div id="topicVersionRevision">Topic 14675 Version 63.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Rosenbaum JF, Ionescu DF. Fluoxetine. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.335.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Roseboom, PH, Kalin, NH. Citalopram and escitalopram. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.431.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Howlett JR, Stein MB, Nemeroff CB. Paroxetine. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.385.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Carpenter LL, Schatzberg AF. Sertraline. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.359.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Aboujaoude E, Koran LM. Fluvoxamine. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.419.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18923511" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The molecular neurobiology of depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9068931" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9068931" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9068931" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9068931" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9068931" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9068931" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30726237" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Predicting inadequate postoperative pain management in depressed patients: A machine learning approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28910830" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17088502" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10964858" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Timing of onset of antidepressant response with fluoxetine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16390886" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25974703" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31178367" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31178368" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Which antidepressant doses are optimal?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26552940" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26552940" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26552940" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26552940" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26552940" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26552940" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28234433" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Caring for the Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32114782" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : QTc Prolongation and Psychotropic Medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20238342" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fluvoxamine versus other anti-depressive agents for depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23879318" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27486148" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18404015" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15291685" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Extrapyramidal symptoms associated with selective serotonin reuptake inhibitors</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393946" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Sertraline versus other antidepressive agents for depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18056231" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485726" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Expanding the black box - depression, antidepressants, and the risk of suicide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485726" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Expanding the black box - depression, antidepressants, and the risk of suicide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24922496" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27005565" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24646010" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Antidepressant use and risk of coronary heart disease: meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25168784" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24549548" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24306340" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23360890" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : QT interval and antidepressant use: a cross sectional study of electronic health records.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22748401" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23640689" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27166093" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Outcomes of Citalopram Dosage Risk Mitigation in a Veteran Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27736049" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : High-Dose Citalopram and Escitalopram and the Risk of Out-of-Hospital Death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24399423" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cardiac safety concerns remain for citalopram at dosages above 40 mg/day.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24399424" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Safety of high-dosage citalopram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23928296" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The cardiovascular safety profile of escitalopram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22820898" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24724757" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Case report, aetiology, and treatment of an acquired long-QT syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22133983" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26155373" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effects of Escitalopram on Autonomic Function in Posttraumatic Stress Disorder Among Veterans of Operations Enduring Freedom and Iraqi Freedom (OEF/OIF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27741028" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Pharmacokinetics and effect on the corrected QT interval of single-dose escitalopram in healthy elderly compared with younger adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28770276" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A comparative study of QT prolongation with serotonin reuptake inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30676405" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Selective Serotonin Reuptake Inhibitors and Fertility: Considerations for Couples Trying to Conceive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15491240" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10450256" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Changes in weight during a 1-year trial of fluoxetine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10363731" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19721108" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Adverse reactions to antidepressants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1852793" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11981349" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12817155" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12817155" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12817155" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12817155" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11105740" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11282808" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9065681" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1540762" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Sertraline in the prevention of depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10926053" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Weight gain and antidepressants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19474754" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19339356" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24876088" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Selective serotonin reuptake inhibitors and risk of cerebral bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27918771" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Association of Selective Serotonin Reuptake Inhibitors With the Risk for Spontaneous Intracranial Hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18606952" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18227365" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27918755" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Selective Serotonin Reuptake Inhibitors and Intracranial Hemorrhage: Deriving Clinical Relevance From an Epidemiologic Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23152272" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23362083" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Selective serotonin reuptake inhibitors for stroke recovery: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30081645" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Clinical Management of Bleeding Risk With Antidepressants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27514297" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Serotonin Reuptake Inhibitors and Risk of Abnormal Bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27521835" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21948719" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26173947" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23077009" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26658443" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Antidepressant Use Is Associated With an Increased Risk of Developing Microbleeds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28383363" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Cerebrovascular, Cardiovascular, and Mortality Events in New Users of Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors: A Propensity Score-Matched Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28841484" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Can we recommend mirtazapine and bupropion for patients at risk for bleeding?: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28841484" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Can we recommend mirtazapine and bupropion for patients at risk for bleeding?: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28841484" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Can we recommend mirtazapine and bupropion for patients at risk for bleeding?: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21190637" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24777151" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24993365" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28543334" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The use of selective serotonin receptor inhibitors (SSRIs) is not associated with increased risk of endoscopy-refractory bleeding, rebleeding or mortality in peptic ulcer bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24789076" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Influence of pre-operative use of serotonergic antidepressants (SADs) on the risk of bleeding in patients undergoing different surgical interventions: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29210786" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors Are Not Associated With Bleeding or Transfusion in Cardiac Surgical Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23077011" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Estimating treatment effects in observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24477492" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28994901" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Risk of First Onset Stroke in SSRI-Exposed Adult Subjects: Survival Analysis and Examination of Age and Time Effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32865558" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Association of Selective Serotonin Reuptake Inhibitor Use After Intracerebral Hemorrhage With Hemorrhage Recurrence and Depression Severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25355829" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Explanatory factors for the increased mortality of stroke patients with depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24893612" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Impact of prestroke selective serotonin reuptake inhibitor treatment on stroke severity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27773479" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Second-Generation Antidepressants and Hyponatremia Risk: A Population-Based Cohort Study of Older Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21777511" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28923523" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Antidepressants and Hyponatremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27194321" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Antidepressants and the risk of hyponatremia: a Danish register-based population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28803926" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Differences in Associations of Antidepressants and Hospitalization Due to Hyponatremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33485536" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Corrigendum to "Differences in Associations of Antidepressants and Hospitalization Due to Hyponatremia" AmJMed, 131(01);56-63.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30753762" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Antidepressants, Mood Stabilizers, Antipsychotics, and the Risk of Cataract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29409486" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Antidepressants use and risk of cataract development: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30096594" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : The risk of glaucoma and serotonergic antidepressants: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30096594" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : The risk of glaucoma and serotonergic antidepressants: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32475742" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Associations between selective serotonin reuptake inhibitors and violent crime in adolescents, young, and older adults - a Swedish register-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28457149" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : A Cruel Irony for Clinicians Who Treat Depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28135844" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Morbidity and Mortality Associated With Medications Used in the Treatment of Depression: An Analysis of Cases Reported to U.S. Poison Control Centers, 2000-2014.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
